AU618143B2 - Cdna clones coding for polypeptides exhibiting multi- lineage cellular growth factor activity and/or mast cell growth factor activity - Google Patents
Cdna clones coding for polypeptides exhibiting multi- lineage cellular growth factor activity and/or mast cell growth factor activity Download PDFInfo
- Publication number
- AU618143B2 AU618143B2 AU44439/89A AU4443989A AU618143B2 AU 618143 B2 AU618143 B2 AU 618143B2 AU 44439/89 A AU44439/89 A AU 44439/89A AU 4443989 A AU4443989 A AU 4443989A AU 618143 B2 AU618143 B2 AU 618143B2
- Authority
- AU
- Australia
- Prior art keywords
- growth factor
- factor activity
- leu
- polypeptide
- mammalian
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 230000000694 effects Effects 0.000 title claims description 78
- 108010002386 Interleukin-3 Proteins 0.000 title claims description 72
- 108010039445 Stem Cell Factor Proteins 0.000 title claims description 62
- 229920001184 polypeptide Polymers 0.000 title claims description 51
- 108090000765 processed proteins & peptides Proteins 0.000 title claims description 51
- 102000004196 processed proteins & peptides Human genes 0.000 title claims description 51
- 239000003102 growth factor Substances 0.000 title claims description 33
- 230000010261 cell growth Effects 0.000 title claims description 30
- 230000001747 exhibiting effect Effects 0.000 title claims description 25
- 102100020880 Kit ligand Human genes 0.000 title 1
- 210000004027 cell Anatomy 0.000 claims description 133
- 239000002299 complementary DNA Substances 0.000 claims description 98
- 102100039064 Interleukin-3 Human genes 0.000 claims description 70
- 108020004414 DNA Proteins 0.000 claims description 61
- 238000000034 method Methods 0.000 claims description 56
- 102000053602 DNA Human genes 0.000 claims description 54
- 108020004999 messenger RNA Proteins 0.000 claims description 39
- 108090000623 proteins and genes Proteins 0.000 claims description 35
- 239000002773 nucleotide Substances 0.000 claims description 26
- 125000003729 nucleotide group Chemical group 0.000 claims description 26
- 239000013598 vector Substances 0.000 claims description 25
- 230000008569 process Effects 0.000 claims description 17
- 102000004169 proteins and genes Human genes 0.000 claims description 17
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 16
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 claims description 15
- 230000014509 gene expression Effects 0.000 claims description 13
- 108091026890 Coding region Proteins 0.000 claims description 11
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 10
- 210000004962 mammalian cell Anatomy 0.000 claims description 10
- 150000007523 nucleic acids Chemical group 0.000 claims description 10
- 150000001413 amino acids Chemical group 0.000 claims description 9
- 239000013604 expression vector Substances 0.000 claims description 9
- 230000008488 polyadenylation Effects 0.000 claims description 9
- 238000000338 in vitro Methods 0.000 claims description 6
- 244000005700 microbiome Species 0.000 claims description 6
- 238000013518 transcription Methods 0.000 claims description 6
- 230000035897 transcription Effects 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 108020004511 Recombinant DNA Proteins 0.000 claims description 3
- 230000002708 enhancing effect Effects 0.000 claims description 3
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 241001529936 Murinae Species 0.000 claims 2
- CCUAQNUWXLYFRA-IMJSIDKUSA-N Ala-Asn Chemical compound C[C@H]([NH3+])C(=O)N[C@H](C([O-])=O)CC(N)=O CCUAQNUWXLYFRA-IMJSIDKUSA-N 0.000 claims 1
- VJVQKGYHIZPSNS-FXQIFTODSA-N Ala-Ser-Arg Chemical compound C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCN=C(N)N VJVQKGYHIZPSNS-FXQIFTODSA-N 0.000 claims 1
- YSUVMPICYVWRBX-VEVYYDQMSA-N Arg-Asp-Thr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O YSUVMPICYVWRBX-VEVYYDQMSA-N 0.000 claims 1
- GXMSVVBIAMWMKO-BQBZGAKWSA-N Asn-Arg-Gly Chemical compound NC(=O)C[C@H](N)C(=O)N[C@H](C(=O)NCC(O)=O)CCCN=C(N)N GXMSVVBIAMWMKO-BQBZGAKWSA-N 0.000 claims 1
- TWXZVVXRRRRSLT-IMJSIDKUSA-N Asn-Cys Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CS)C(O)=O TWXZVVXRRRRSLT-IMJSIDKUSA-N 0.000 claims 1
- HXWUJJADFMXNKA-BQBZGAKWSA-N Asn-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CC(N)=O HXWUJJADFMXNKA-BQBZGAKWSA-N 0.000 claims 1
- DWOGMPWRQQWPPF-GUBZILKMSA-N Asp-Leu-Glu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O DWOGMPWRQQWPPF-GUBZILKMSA-N 0.000 claims 1
- LIJXJYGRSRWLCJ-IHRRRGAJSA-N Asp-Phe-Arg Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O LIJXJYGRSRWLCJ-IHRRRGAJSA-N 0.000 claims 1
- HBHMVBGGHDMPBF-GARJFASQSA-N Cys-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CS)N HBHMVBGGHDMPBF-GARJFASQSA-N 0.000 claims 1
- SNFUTDLOCQQRQD-ZKWXMUAHSA-N Glu-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H](N)CCC(O)=O SNFUTDLOCQQRQD-ZKWXMUAHSA-N 0.000 claims 1
- JENKOCSDMSVWPY-SRVKXCTJSA-N His-Leu-Asn Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O JENKOCSDMSVWPY-SRVKXCTJSA-N 0.000 claims 1
- AIPUZFXMXAHZKY-QWRGUYRKSA-N His-Leu-Gly Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O AIPUZFXMXAHZKY-QWRGUYRKSA-N 0.000 claims 1
- 101001033279 Homo sapiens Interleukin-3 Proteins 0.000 claims 1
- 101000716729 Homo sapiens Kit ligand Proteins 0.000 claims 1
- PDTMWFVVNZYWTR-NHCYSSNCSA-N Ile-Gly-Lys Chemical compound CC[C@H](C)[C@H](N)C(=O)NCC(=O)N[C@@H](CCCCN)C(O)=O PDTMWFVVNZYWTR-NHCYSSNCSA-N 0.000 claims 1
- SENJXOPIZNYLHU-UHFFFAOYSA-N L-leucyl-L-arginine Natural products CC(C)CC(N)C(=O)NC(C(O)=O)CCCN=C(N)N SENJXOPIZNYLHU-UHFFFAOYSA-N 0.000 claims 1
- SENJXOPIZNYLHU-IUCAKERBSA-N Leu-Arg Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(O)=O)CCCN=C(N)N SENJXOPIZNYLHU-IUCAKERBSA-N 0.000 claims 1
- DNDWZFHLZVYOGF-KKUMJFAQSA-N Leu-Leu-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O DNDWZFHLZVYOGF-KKUMJFAQSA-N 0.000 claims 1
- OVZLLFONXILPDZ-VOAKCMCISA-N Leu-Lys-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O OVZLLFONXILPDZ-VOAKCMCISA-N 0.000 claims 1
- NJNRBRKHOWSGMN-SRVKXCTJSA-N Lys-Leu-Asn Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O NJNRBRKHOWSGMN-SRVKXCTJSA-N 0.000 claims 1
- WLXGMVVHTIUPHE-ULQDDVLXSA-N Lys-Phe-Val Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(O)=O WLXGMVVHTIUPHE-ULQDDVLXSA-N 0.000 claims 1
- CHDYFPCQVUOJEB-ULQDDVLXSA-N Met-Leu-Phe Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 CHDYFPCQVUOJEB-ULQDDVLXSA-N 0.000 claims 1
- 101100005318 Mus musculus Ctsr gene Proteins 0.000 claims 1
- KZNQNBZMBZJQJO-UHFFFAOYSA-N N-glycyl-L-proline Natural products NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 claims 1
- LZDIENNKWVXJMX-JYJNAYRXSA-N Phe-Arg-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC1=CC=CC=C1 LZDIENNKWVXJMX-JYJNAYRXSA-N 0.000 claims 1
- FXPZZKBHNOMLGA-HJWJTTGWSA-N Phe-Ile-Arg Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)N FXPZZKBHNOMLGA-HJWJTTGWSA-N 0.000 claims 1
- ZTVSVSFBHUVYIN-UFYCRDLUSA-N Phe-Tyr-Met Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(O)=O)NC(=O)[C@@H](N)CC=1C=CC=CC=1)C1=CC=C(O)C=C1 ZTVSVSFBHUVYIN-UFYCRDLUSA-N 0.000 claims 1
- HAEGAELAYWSUNC-WPRPVWTQSA-N Pro-Gly-Val Chemical compound [H]N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O HAEGAELAYWSUNC-WPRPVWTQSA-N 0.000 claims 1
- WFUAUEQXPVNAEF-ZJDVBMNYSA-N Thr-Arg-Thr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)O)C(O)=O)CCCN=C(N)N WFUAUEQXPVNAEF-ZJDVBMNYSA-N 0.000 claims 1
- BKVICMPZWRNWOC-RHYQMDGZSA-N Thr-Val-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)[C@@H](C)O BKVICMPZWRNWOC-RHYQMDGZSA-N 0.000 claims 1
- VKYDVKAKGDNZED-STECZYCISA-N Tyr-Val-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC1=CC=C(C=C1)O)N VKYDVKAKGDNZED-STECZYCISA-N 0.000 claims 1
- DDNIHOWRDOXXPF-NGZCFLSTSA-N Val-Asp-Pro Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N1CCC[C@@H]1C(=O)O)N DDNIHOWRDOXXPF-NGZCFLSTSA-N 0.000 claims 1
- 108010029539 arginyl-prolyl-proline Proteins 0.000 claims 1
- 108010062796 arginyllysine Proteins 0.000 claims 1
- 108010040443 aspartyl-aspartic acid Proteins 0.000 claims 1
- SSJJWVREPZVNBF-DGXVIIAXSA-N dG10 Chemical compound C1=NC(C(NC(N)=N2)=O)=C2N1[C@H](O[C@@H]1COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)CO)C[C@@H]1OP(O)(=O)OC[C@@H](O1)[C@@H](O)C[C@@H]1N1C(N=C(NC2=O)N)=C2N=C1 SSJJWVREPZVNBF-DGXVIIAXSA-N 0.000 claims 1
- KZNQNBZMBZJQJO-YFKPBYRVSA-N glyclproline Chemical compound NCC(=O)N1CCC[C@H]1C(O)=O KZNQNBZMBZJQJO-YFKPBYRVSA-N 0.000 claims 1
- 108010077515 glycylproline Proteins 0.000 claims 1
- 102000055151 human KITLG Human genes 0.000 claims 1
- 108010049589 leucyl-leucyl-leucine Proteins 0.000 claims 1
- 108010000761 leucylarginine Proteins 0.000 claims 1
- 108010057821 leucylproline Proteins 0.000 claims 1
- 108700023046 methionyl-leucyl-phenylalanine Proteins 0.000 claims 1
- 235000015097 nutrients Nutrition 0.000 claims 1
- 108010082795 phenylalanyl-arginyl-arginine Proteins 0.000 claims 1
- 108020004635 Complementary DNA Proteins 0.000 description 91
- 238000010804 cDNA synthesis Methods 0.000 description 89
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 76
- 210000003593 megakaryocyte Anatomy 0.000 description 43
- 239000007983 Tris buffer Substances 0.000 description 31
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 31
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 28
- 210000003630 histaminocyte Anatomy 0.000 description 25
- 239000008188 pellet Substances 0.000 description 24
- 239000000523 sample Substances 0.000 description 24
- 239000013612 plasmid Substances 0.000 description 23
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 20
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 20
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 20
- 239000000243 solution Substances 0.000 description 20
- 239000006228 supernatant Substances 0.000 description 20
- 239000012894 fetal calf serum Substances 0.000 description 19
- 239000000203 mixture Substances 0.000 description 19
- 210000001744 T-lymphocyte Anatomy 0.000 description 18
- 210000000287 oocyte Anatomy 0.000 description 17
- 239000000872 buffer Substances 0.000 description 15
- 241000588724 Escherichia coli Species 0.000 description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
- 238000009396 hybridization Methods 0.000 description 14
- 235000018102 proteins Nutrition 0.000 description 14
- 210000002540 macrophage Anatomy 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 238000003556 assay Methods 0.000 description 11
- 210000002798 bone marrow cell Anatomy 0.000 description 11
- 210000003979 eosinophil Anatomy 0.000 description 11
- 238000011534 incubation Methods 0.000 description 11
- 238000002347 injection Methods 0.000 description 11
- 239000007924 injection Substances 0.000 description 11
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 11
- 210000003719 b-lymphocyte Anatomy 0.000 description 10
- 210000000130 stem cell Anatomy 0.000 description 10
- 238000001890 transfection Methods 0.000 description 10
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 9
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 9
- 229940098773 bovine serum albumin Drugs 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 239000012634 fragment Substances 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 210000003743 erythrocyte Anatomy 0.000 description 8
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 8
- 210000003714 granulocyte Anatomy 0.000 description 8
- 230000012010 growth Effects 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 210000000952 spleen Anatomy 0.000 description 8
- 108020004705 Codon Proteins 0.000 description 7
- 108010002350 Interleukin-2 Proteins 0.000 description 7
- 102000000588 Interleukin-2 Human genes 0.000 description 7
- 125000003275 alpha amino acid group Chemical group 0.000 description 7
- 229940076264 interleukin-3 Drugs 0.000 description 7
- 238000002955 isolation Methods 0.000 description 7
- 230000004048 modification Effects 0.000 description 7
- 238000012986 modification Methods 0.000 description 7
- 230000010076 replication Effects 0.000 description 7
- 239000011734 sodium Substances 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 241000282693 Cercopithecidae Species 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 108091036060 Linker DNA Proteins 0.000 description 6
- 102000008072 Lymphokines Human genes 0.000 description 6
- 108010074338 Lymphokines Proteins 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- 210000002960 bfu-e Anatomy 0.000 description 6
- 230000009089 cytolysis Effects 0.000 description 6
- 230000000925 erythroid effect Effects 0.000 description 6
- 239000003797 essential amino acid Substances 0.000 description 6
- 235000020776 essential amino acid Nutrition 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 230000028993 immune response Effects 0.000 description 6
- 210000004698 lymphocyte Anatomy 0.000 description 6
- 210000003643 myeloid progenitor cell Anatomy 0.000 description 6
- 210000000440 neutrophil Anatomy 0.000 description 6
- 239000013600 plasmid vector Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 239000011782 vitamin Substances 0.000 description 6
- 229940088594 vitamin Drugs 0.000 description 6
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 5
- 239000005695 Ammonium acetate Substances 0.000 description 5
- 102100031780 Endonuclease Human genes 0.000 description 5
- 108010042407 Endonucleases Proteins 0.000 description 5
- 239000000020 Nitrocellulose Substances 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- 229940024606 amino acid Drugs 0.000 description 5
- 229940043376 ammonium acetate Drugs 0.000 description 5
- 235000019257 ammonium acetate Nutrition 0.000 description 5
- 229960000723 ampicillin Drugs 0.000 description 5
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 5
- 210000001185 bone marrow Anatomy 0.000 description 5
- 244000309466 calf Species 0.000 description 5
- 239000006285 cell suspension Substances 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 229920002678 cellulose Polymers 0.000 description 5
- 239000001913 cellulose Substances 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 230000000295 complement effect Effects 0.000 description 5
- 239000003636 conditioned culture medium Substances 0.000 description 5
- 230000029087 digestion Effects 0.000 description 5
- 230000003394 haemopoietic effect Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 229920001220 nitrocellulos Polymers 0.000 description 5
- 239000005720 sucrose Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 230000014616 translation Effects 0.000 description 5
- 235000013343 vitamin Nutrition 0.000 description 5
- 229930003231 vitamin Natural products 0.000 description 5
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 4
- 238000010600 3H thymidine incorporation assay Methods 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 102100033215 DNA nucleotidylexotransferase Human genes 0.000 description 4
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 4
- 102100034343 Integrase Human genes 0.000 description 4
- 239000008272 agar Substances 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 4
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- YQOKLYTXVFAUCW-UHFFFAOYSA-N guanidine;isothiocyanic acid Chemical compound N=C=S.NC(N)=N YQOKLYTXVFAUCW-UHFFFAOYSA-N 0.000 description 4
- 229920000609 methyl cellulose Polymers 0.000 description 4
- 239000001923 methylcellulose Substances 0.000 description 4
- 235000010981 methylcellulose Nutrition 0.000 description 4
- 229960002900 methylcellulose Drugs 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- 102000012410 DNA Ligases Human genes 0.000 description 3
- 108010061982 DNA Ligases Proteins 0.000 description 3
- 102000004594 DNA Polymerase I Human genes 0.000 description 3
- 108010017826 DNA Polymerase I Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
- 239000013614 RNA sample Substances 0.000 description 3
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
- 108091081024 Start codon Proteins 0.000 description 3
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 3
- 241000269368 Xenopus laevis Species 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000001143 conditioned effect Effects 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 3
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 239000012149 elution buffer Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000012869 ethanol precipitation Methods 0.000 description 3
- 238000005194 fractionation Methods 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 210000003292 kidney cell Anatomy 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 229930182817 methionine Natural products 0.000 description 3
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 238000007747 plating Methods 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000001632 sodium acetate Substances 0.000 description 3
- 235000017281 sodium acetate Nutrition 0.000 description 3
- 210000004989 spleen cell Anatomy 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 239000001226 triphosphate Substances 0.000 description 3
- 235000011178 triphosphate Nutrition 0.000 description 3
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- LTFMZDNNPPEQNG-KVQBGUIXSA-N 2'-deoxyguanosine 5'-monophosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@H]1C[C@H](O)[C@@H](COP(O)(O)=O)O1 LTFMZDNNPPEQNG-KVQBGUIXSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 108010062580 Concanavalin A Proteins 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 102000003951 Erythropoietin Human genes 0.000 description 2
- 108090000394 Erythropoietin Proteins 0.000 description 2
- 241000272184 Falconiformes Species 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 239000007760 Iscove's Modified Dulbecco's Medium Substances 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 101001043827 Mus musculus Interleukin-2 Proteins 0.000 description 2
- 101001033276 Mus musculus Interleukin-3 Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 108091006629 SLC13A2 Proteins 0.000 description 2
- 241000269370 Xenopus <genus> Species 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- IFLVGRRVGPXYON-UHFFFAOYSA-N adci Chemical compound C12=CC=CC=C2C2(C(=O)N)C3=CC=CC=C3CC1N2 IFLVGRRVGPXYON-UHFFFAOYSA-N 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 239000012148 binding buffer Substances 0.000 description 2
- 210000003969 blast cell Anatomy 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 235000011089 carbon dioxide Nutrition 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000008614 cellular interaction Effects 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000001332 colony forming effect Effects 0.000 description 2
- 230000002281 colonystimulating effect Effects 0.000 description 2
- 238000007398 colorimetric assay Methods 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 2
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 2
- GYOZYWVXFNDGLU-XLPZGREQSA-N dTMP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)C1 GYOZYWVXFNDGLU-XLPZGREQSA-N 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 229960002086 dextran Drugs 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 229940105423 erythropoietin Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 229920001519 homopolymer Polymers 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 210000001778 pluripotent stem cell Anatomy 0.000 description 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 210000000689 upper leg Anatomy 0.000 description 2
- NCMVOABPESMRCP-SHYZEUOFSA-N 2'-deoxycytosine 5'-monophosphate Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)C1 NCMVOABPESMRCP-SHYZEUOFSA-N 0.000 description 1
- IHPYMWDTONKSCO-UHFFFAOYSA-N 2,2'-piperazine-1,4-diylbisethanesulfonic acid Chemical compound OS(=O)(=O)CCN1CCN(CCS(O)(=O)=O)CC1 IHPYMWDTONKSCO-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- OSJPPGNTCRNQQC-UWTATZPHSA-N 3-phospho-D-glyceric acid Chemical compound OC(=O)[C@H](O)COP(O)(O)=O OSJPPGNTCRNQQC-UWTATZPHSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 244000153158 Ammi visnaga Species 0.000 description 1
- 235000010585 Ammi visnaga Nutrition 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 108010089921 CTCGAG-specific type II deoxyribonucleases Proteins 0.000 description 1
- 108010072454 CTGCAG-specific type II deoxyribonucleases Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 108010051152 Carboxylesterase Proteins 0.000 description 1
- 102000013392 Carboxylesterase Human genes 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 108020004394 Complementary RNA Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- 108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 101710140859 E3 ubiquitin ligase TRAF3IP2 Proteins 0.000 description 1
- 102100026620 E3 ubiquitin ligase TRAF3IP2 Human genes 0.000 description 1
- 102100021587 Embryonic testis differentiation protein homolog A Human genes 0.000 description 1
- 241001646716 Escherichia coli K-12 Species 0.000 description 1
- 241001288713 Escherichia coli MC1061 Species 0.000 description 1
- 102000020897 Formins Human genes 0.000 description 1
- 108091022623 Formins Proteins 0.000 description 1
- 108010089133 GGTACC-specific type II deoxyribonucleases Proteins 0.000 description 1
- 108010041896 GTYRAC-specific type II deoxyribonucleases Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101000777314 Homo sapiens Choline kinase alpha Proteins 0.000 description 1
- 101000777313 Homo sapiens Choline/ethanolamine kinase Proteins 0.000 description 1
- 101000898120 Homo sapiens Embryonic testis differentiation protein homolog A Proteins 0.000 description 1
- 101001138544 Homo sapiens UMP-CMP kinase Proteins 0.000 description 1
- 241000701109 Human adenovirus 2 Species 0.000 description 1
- 101710203526 Integrase Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102100024319 Intestinal-type alkaline phosphatase Human genes 0.000 description 1
- 101710184243 Intestinal-type alkaline phosphatase Proteins 0.000 description 1
- 102000002397 Kinins Human genes 0.000 description 1
- 108010093008 Kinins Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101000777315 Mus musculus Choline kinase alpha Proteins 0.000 description 1
- 101000777310 Mus musculus Choline/ethanolamine kinase Proteins 0.000 description 1
- 101000974705 Mus musculus UMP-CMP kinase Proteins 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 230000004988 N-glycosylation Effects 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 101000920676 Ovis aries Erythropoietin Proteins 0.000 description 1
- 239000007990 PIPES buffer Substances 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108010087702 Penicillinase Proteins 0.000 description 1
- 241000157426 Pernis Species 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
- 108010076181 Proinsulin Proteins 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 108020005067 RNA Splice Sites Proteins 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 102100038803 Somatotropin Human genes 0.000 description 1
- 208000019229 Spleen disease Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 101150052863 THY1 gene Proteins 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 240000000359 Triticum dicoccon Species 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 241001672648 Vieira Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 239000013602 bacteriophage vector Substances 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- HXNZTJULPKRNPR-UHFFFAOYSA-N borinine Chemical compound B1=CC=CC=C1 HXNZTJULPKRNPR-UHFFFAOYSA-N 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- YTRQFSDWAXHJCC-UHFFFAOYSA-N chloroform;phenol Chemical compound ClC(Cl)Cl.OC1=CC=CC=C1 YTRQFSDWAXHJCC-UHFFFAOYSA-N 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 229940047120 colony stimulating factors Drugs 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 210000003013 erythroid precursor cell Anatomy 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000012847 fine chemical Substances 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000002414 glycolytic effect Effects 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 230000001744 histochemical effect Effects 0.000 description 1
- 210000004754 hybrid cell Anatomy 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 229940088592 immunologic factor Drugs 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000010841 mRNA extraction Methods 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- -1 methyl- Chemical group 0.000 description 1
- 238000001471 micro-filtration Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- SLCVBVWXLSEKPL-UHFFFAOYSA-N neopentyl glycol Chemical compound OCC(C)(C)CO SLCVBVWXLSEKPL-UHFFFAOYSA-N 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229950009506 penicillinase Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 238000013492 plasmid preparation Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000000734 protein sequencing Methods 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 108020004418 ribosomal RNA Proteins 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 229940043517 specific immunoglobulins Drugs 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 229940063673 spermidine Drugs 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000000856 sucrose gradient centrifugation Methods 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Description
-L
618143 COMMONWEALTH OF -AUSTRALIA PATENTS ACT1 im5 DIVISIONAL SPECIFICATION
(ORIGINAL)
FOR OFFICE USE Form :10 It Short ruio: hIt. Cl: Application Number:- Lodged: 4 4. 4 4 4 4 4 4 4 4 Complete Specification-Lodged: Accep ted: Lapsed: Published: Priority: Related Art: 4 4 4 4 40 44 TO BE COMPLETED BY APPLICANT 42 Name ofApplicant: Address of Applicant: Actual Inventor: Address for Service: SCI-ERING BIOTECH CORPORATION 1454 Page Mill Road, Palo Alto, California 94304, U.S.A.
TAKASHI YOKOTA, FRANK DON LEE, DONNA MAYE RENNICK and KEN-ICI
ARAI
GRIFF1TH1-lACK CO.
71 YORK STREET SYDNEY NSW 2000
AUSTRALIA
Complete Specification for the invention entitled: "eDNA CLONES CODING FOR POLYPEPTIDES EXHIBITING MULTI-LINEAGE CELLULAR GROWTH FACTOR ACTIVITY AND/ORt MAST CE~LL GROWTH4 FACTOR ACTIVITY" I'lia following statement is a full description of this invention, including the best method of performing it luiown to me/us:- 9258/NL i cDNA CLONES CODING FOR POLYPEPTIDES EXHIBITING MULTI-LINEAGE CELLULAR GROWTH FACTOR ACTIVITY AND/OR MAST CELL GROWTH FACTOR ACTIVITY This invention relates generally to the 5 application of recombinant DNA technology to elucidate S* the control mechanisms of the mammalian immune response and, more particularly, to the isolation of *r deoxyribonucleic acid (DNA) clones coding for polypeptides exhibiting multi-lineage cellular growth factor activity and/or mast cell growth factor activity.
Recombinant DNA technology refers generally to the technique of integrating genetic information from a donor source into vectors for subsequent processing, 1 such as through introduction into a host, whereby the 15 transferred genetic information is copied and/or expressed in the new environment. Commonly, the genetic S. information exists in the form of complementary DNA S (cDNA) derived from messenger RNA (mRNA) coding for a .desired protein product. The carrier is frequently a plasmid having the capacity to incorporate cDNA for later replication in a host and, in some cases, actually to control expression of the cDNA and thereby direct synthesis of the encoded product in the host.
This technology has progressed extremely rapidly in recent years, and a variety of exogenous proteins have been expressed in a variety of hosts. By way of example, some of the eukaryotic protola~ soproduced include: proinsulin (Naber, S. et al., Gene 21: 95-104 [1983])) interferons (Simon, L. et al., Proc. Nat. Acad. Seti 80: 2059-2062 [1983] and Derynck R, at ele, Nucl. Acids Ros. 1: 1819-1837 [1983)); and growth hormone (Gooddel, et al., Nature 281: 544-548 [1979)). (These publications and other referenced materilis have been included to provide additional details on the background of the pertinent are and, in particular instances, the practice of invention, and are all incorporated herein by reference.) For some time, it has been dogma that the .mammalian immune response was due primarily to a series S of complex cellular interactions, called the "immune network". While it remains clear that much of the response does in fact revolve around the network-like interactions of lymphocytes, macrophagen, granulocytes and other cells, immunologists now generally hold the 2. opinion that soluble proteins the so-called lymphokines) play a critical role in controlling these cellular interactions.
Lymphokines apparently mediate cellular activities in a variety of ways, They have been shown to have the ability to support the proliferation and growth of various lymphocytes and, indeed, are thought to play a crucial role in the basic differentiation of pluripotential hematopoietic stem cells into the vast number of progenitors of the diverse cellular linea.is responsible for the immune response. Cell lineages important in this response include two classes of lymphocytes: B cells, which can produce and secrete immunoglobulins (proteins with the capability of recognizing and binding to foreign matter to effect its -3nomral), and T cells (of various Gubsets) thatid'c or suppress B cells anl come of the, other cells (including other T cells) making up the immune network.
Another important,- cell lineage is the mast cell a ganule-containing connective tissue Coll located proximate to capillaries throughout the bcdy, with especially high concentrations in the lungs, skin, and gastrointestinal and genitourinary tracts. M asnt coils play a central role in allergy-related disordera, particularly anaphylaxig, ani this role can be briefly stated as follows: once certain antigens crosslink, special immunoglobulins bound to receptoro on the mast cell surface, the mast cell degranulates and releases the mediators histamine, serotonint heparin, kinins, etc.) which cause allergic reactions# eog.
Research to better Understand (and thus potentially tre at therapeutically) allergy, anaphylaxis and other immune disorders, through the study of mast cellst T ceils and the other cells involved in the immune response, has been hampered by the general inability to maintain these cells in viro However, several immunologists recently discovered that such cells could be isolated and cultured by growing them on S 25 secretions from other L.ells, conditioned media from splenic lymphocytes stimulated with Concanavalin A It has now become clear from this work that the *'generation of cell clones is dependent on specific factors, such as lymphokines.
Apparently alm~ost all blood cell types are Continuously generated in the adult vertebrate bone marrow through the growth and differentiation of the hierarchy of hematopoietic progenitor cells. At the apex of this hierarchy is the pluripotent stem cell, -4which can repopulate a lethally irradiated animal for most, if not all, immunological cell types red cells, platelets, lymphocytes, various granulocytes and monocytes/macrophages). The pluripotent cell not only S has the capacity to regenerate the pluripotent stem cell compartments (self-renewal), but also gives rise to progenitor cells committed to development along one particular lineage pathway. Progeny of a particular committed stem cell appear to share the same lineage commitment as the parent cell (Metcalf, "Hemopoietic Colonies", Springer Publishing Co., New York, N.Y.
[1977]).
1 if In vitro studies on hematopoiesis have shown I that a number of soluble colony stimulating factors i 15 (CSF) can regulate the growth of these various progenitor cells. Some of these factors have been partially purified and shown to affect specifically stem t cells belonging to a particular cell lineage. For example, erythropoietin stimulates more-differentiated members of the erythroid hierarchy (Miyake, et al., J. Biol. Chem 252: 5558 (1977]), and another factor I (colony stimulating factor-macrophage or CSF-1) preferentially stimulates macrophage growth in semisolid cultures of bone marrow cells (Stanley, and 25 Heard, J. Biol. Chem. 252: 4305 [1977]). Yet wr** another type of growth factor seems able to stimulate hematopoietic colonies consisting of single cell types L S* and mixtures of cells. The range of cells, e.g.
erythrocytes, megakaryocytes, granulocytes, mast cells and monocyte/macrophages, that are responsive to one factor of this second type have caused it to be named a multi-lineage cellular growth factor (multi-CSF) (Iscove, N. et al., J. Cell. Physiol. Suppl., 1: 65-78 (1982]), indicating its capability of affecting a number
L
Q
oZ committed progenitor cells, and perhaps pluripotential stem cells as well.
One of the better characterized factors is interleukin-1 a factor released from macrophages, which induces replication of thymocytes and peripheral T cells (Mizel, S. et al., J. Immunol. 120: 1497-1503 [1978]). Similarly, interleukin-2 (IL-2) and interleukin-3 (IL-3) are two well-studied lymphokines released by certain stimulated lymphocytes. A very significant characteristic of IL-2 is its ability to support the continuous growth of certain T cells in vitro (Farrar et al., Ann. N.Y. Acad. Sci. 332: 303-15 [1979]). Likewise, an important characteristic of IL-3 is its ability to support the growth of cell lines 15 having the phenotypic characteristics of mast cells '(Ihle, J. et al., Immunological Rev. 63: 5-32 [f9'82).
A number of other cellular growth properties have been ascribed to IL-3 as well (see Ihle, J. et al., a.
Immunol. 131: 282-287 and 129: 2431 (1981]), but its precise relationship with multi-CSF has been unclear.
lea Whereas both mouse IL-2 and IL-3 have been at o least partially characterized biochemically (Gillis, S.
et al., J. Immunol. 124: 1954-1962 [1980] and Ihle, J.
et al., J. Immunol. 129: 2431-2436 [1982], *r 25 respectively), IL-2 is presently the accepted primary factor responsible for T-cell growth, whereas the protein(s) responsible for mast cell growth factor (MCGF) and CSF activity have not been agreed upon to the same extent. It is now thought that mouse IL-2 has a molecular weight (probably as a dimer) of approximately 30-35,000 (Simon, P. et al., J. Immunol. 122: 127-132 [1979]), although some variations are recognized (Robb, R. and Smith, Molec. Immun. 18: 1087-1094 [1981]); and human IL-2 apparently has a molecular weight of -6- '.444 4* 44 4 4* 9* 44 4 4 *4*4 4 44*4 4444 444 9444 4*44 4,44 44 4* 4 *4 4 41 *44*44 4 4 4 *4*444 4 4 44 *4 1 4*44 about 15,000 (Gillis, S. et Immun. Rev. 63: 167-209 [1982]). Moreover, a cDNA clone coding for human IL-2 has recently been reported (Taniguchi, T. et al., Nature 302: 305-310 (1983]). On the other hand, mouse mast cell growth factors have been variously reported as having molecular weights of 45,000 (Nabel et al'., Nature, 291: 332-334 (1981],, of 35,000 (Yung, Y. et al., J. Immunol, 127: 794-799 11981]) and of 28,000 (Ihle, J. et al., J. Immunol. 129: 1377-1383 (1982)).
!0 Similar discrepancies surround the CSF's.
Although such molecular weight differences could perhaps be partially explained by varying amounts of glycosylation, clarification of the issue requires additional structural data, substantially full- 15 length sequence analysis of the molecules in question.
Protein sequencing offers, of course, a possible means to solve the problem, but it is very difficult work experimentally and often can provide neither completely accurate nor full-length amino acid sequences.
Moreover, having the capability of making bulk quantities of a polypeptide exhibiting mammalian MCGF or CSF activity will greatly facilitate the study of the biology of mast cells and other cells involved in the immune response; by minimizing the necessity of 25 relying on ConA-conditioned media for stimulating cell growth. Accurate and complete sequence data on an MCGF or CSF will also serve to simplify the search for other immunological factors. Finally, additional information on any lymphokine will help in evaluating the roles of the various growth factors and cells of the immune network and thus provide insight into the entire immune system with the concomitant therapeutic benefits.
Thus, there exists a significant need for extensive nucleotide sequence data on the DNAs coding 0 ii-7for, and amino acid sequences of, proteins exhibiting MCGF or CSF activity, as well as a sim le and economic method of making substantial and essentially pure quantities of such materials. The present invention fulfills these needs.
The present invention provides cDNA clones coding for polypeptides exhibiting mammalian mast cell growth factor (MCGF) activity and or multi-lineage cellular growth factor activity. A nucleotide sequence I0 for a cDNA and a putative amino acid sequence for an associated polypeptide are shown in Figure 1. The cDNA sequence can be integrated into various vectors, which :in turn can direct the synthesis of the corresponding polypeptides in a variety of hosts, including eukaryotic cells, such as mammalian cells in culture.
More specifically, the invention provides a 44:4 process for producing a polypeptide exhibiting mammalian MCGF activity and/or multi-lineage cellular growth factor activity, the process comprising the steps of: a) providing a vector comprising a nucleotide sequence coding for said polypeptide, wherein the nucleotide sequence is capable of being oexpressed by a host containing the vector; I o b) incorporating the vector into the host; and 25 c) maintaining the host containing the vector under conditions suitable for transcription of the nucleotide sequence into said polypeptide.
Preferably, the cDNA sequences are derived from an mRNA sequence coding for the polypeptides, and the host is an organism such as a eukaryotic, e.g.
mammalian, cell transfected or transformed with the vector. Further, the vector preferably comprises also a second nucleotide sequence capable of controlling f 8 expression of the nucleotide sequence coding for the polypeptide. This second sequence coding can include a promoter sequence, one or more intron sequences and a polyadenylation sequence, to permit, respectively, transcription, splicing and polyadenylation of the nucleotide sequence coding for the polypeptide.
Particularly, when the host is a mammalian cell, such as a COS-7 monkey (kidney) cell, the vector contains the promoter sequence of the simian virus 40 (SV40) early region promoter and the polyadenylation sequence of the SV40 late region polyadenylation sequence.
The mouse cDNA sequence of Figure 1 (see below) is capable of hybridizing with other DNA sequences, such as DNA coding for other mammalian growth factors from a cDNA or 0 genomic library. It is noted that the described cDNA S sequences seem to contain information for a leader sequence.
20 The polypeptides of the present invention are capable of enhancing mammalian mast cell and other cell growth, particularly in inJ vt.rQ cultures. Suitable pharmaceutical compositions can be prepared by adding the polypeptides (preparations of which are essentially free of other 25 mammalian growth factors) to therapeutically compatible carriers.
Other features and advantages of the invention will become apparent from the following detailed description, which describes, in conjunction with the accompanying drawings and by way of example, the present invention. The Examples are not intended to limit the scope of the invention in any way.
In the Drawings: Figi 1 illustrates the nucleotide sequence and putative sponding amino acid sequence of a cDNA 7275S/sy -ipV -9clone exhibiting multi-lineage cellular growth factor activity; Figure 2 depicts the amoun. of MCGF activity in fractions of a sucrose gradient sedimentation of mRNA isolated from ConA-stimulated Ci.Ly 1+2-/9 cells, The locations of 18S and 28S ribosomal peaks are indicated; Figure 3 illustrates pcD-MCGL, a plasmid carrying a cDNA clone exhibiting mast cell growth factor activity and multi-lineage cellular growth factor activity; and Figure 4 is a restriction endonuclease cleavage map of the cDNA insert of Figure 3.
TIn Figure 3, transcription of the 950 bp cDNA t: insert contained in the pcD expression vector from the 4 4 SV40 early promoter is indicated by the arrow. The locations of the splice donor ano acceptor sites are shown. The polyadenylation signal, also derived from o.ar SV40, is located at the 3'-end of the cDNA insert. The cDNA insert is heavily shaded. The remainder of the vector sequences are derived from pBR322, includin- the S-lactamase gene (AmpR) and the origin of replication.
44r4 In accordance with the present invention complementary DNA (cDNA) clones are provided for polypeptides exhibiting mammalian mast cell growth j 25 factor (MCGF) activity and/or multi-lineage cellular growth factor (multi-CSF) activity. After the cDNA sequences have been incorporated into replicable expression vectors, and the vectors tranfected into an appropriate host a mammalian cell culture), the expressed polypeptide or polypeptides will possess has the ability to allow the expansion of mast cells and hematopoietic cells to multiple lineages.
An exemplary, putative amino acid sequence based on the isolated nucloeotide sequence is shown in Figure 1. A portion of the predicted sequence (amino acids 33 to 41) is identical with the reported NH 2 terminal sequence of mouse Interleukin-3 which has been shown to exhibit mouse MCGF activity and multi- CSF activity (Ihle, J. et al., J. Immunol. 129, 2431- 2436 (1982); Ihle, J. et al., J. Immunol. 131, 282-287 (1983); and Garland, J. et al., Eds. Oppenheim, J. and Cohen, "Interleukinsi Lymphokines, and Cytosines", Proceedings of Third Int. Lymphokines Workshop, Academic Press, New York, pages 123-129 (1983)). The coding region located between the translation start codon (ASG) and the beginning of the sequence contained in IL-3 is rich in hydrophobic amino acids, as would be expected for a leader sequence of a secreted protein. Therefore, the polypeptide's mature form in vivo, as secreted, possibly begins with an Asp residue, as does IL-3, and the preceding 20 or so amino acids constituting the putative leader sequence are removed by proteolytic processing. Assuming this to be accurate, the mature polypeptide exhibiting MCGF and multi-CSF activities would consist of 134 amino acids, with a calculated molecular weight of about 15,000. Furthermore, the presence of four potential N-glycosylation sites, i.e., Asn-X-Ser (where X is an amino acid residue) at deduced amino acid positions 42-44, 70-72, 77-79, and 112-114 of o. the polypeptide (see Neuberger et al., Glycoproteins 450-490, Elsevier Publishing Co., U.S.A. [1972)), suggests that it would be glycosylated in vivo.
When transfected into COS-7 monkey cells, one of the cDNA clones of this invention directs the synthesis of biologically active MCGF and multi-CSF.
Addition of this expressed cloned gene product to 0 -11- .P 4* 1 *4 4 4 44 a 4 S*4 1*s
*J
4 rr 4 44 44l 4 44o 4r' cultures of mouse bone-marrow cells allows the expansion of hematopoietic cells committed to multiple lineages; it supports the formation of burst-forming erythroid colonies (BFU-E), granulocyte/macrophage colonies (CFUmast cell colonies (CU-mast), as well as colonies of multiple lineages (CFU-Mixed), and sustains multipotential stem cells (CFU-S) in liquid culture.
A variety of methods may be used to prepare the CDNAS of the present invention. By way of example, total mRNA is extracted as reported by Berger, S.
et al,, Biochemistry 18: 5143-5149 [1979]) from a cell line a hybrid cell line) producing polypeptides exhibiting mammalian mast cell growth factor activity.
The double-stranded cDNAs from this total mRNA can be 15 constructed by using primer-initiated reverse transcription (Verma, Biochim. Biophys. Acta, 473: 1-38 11977]) to make first the complement of each mRNA sequence, and then by priming for second strand synthesis (Land, H. et al., Nucleic Acids Res., 9: 2251- 20 2266 [1981]). Subsequently, the cDNAs can be cloned by joining them to suitable plasmid or bacteriophage vectors (Rougeon, F. et al., Nucleic Acids Res., 2, 2365-2378 [19751 or Scherer, G. et al., Dev. Biol. 86, 438-447 (1981]) through complementary homopolymeric 25 tails (Efstratiadis, A. et al., Cell, 10, 571-585 [1977]) or cohesive ends created with linker segments containing appropriate restriction sites (Seeburg, P. et al., Nature, 270, 486-494 [19771 or Shine, J. et al., Nature, 270, 494-499 [1977]), and then transforming a suitable host. (See generally Efstratiadis, and Villa-Kormaroff, "Cloning of double stranded cDNA" in Setlow, J. and Hollaender, A. (eds.) Genetic Engineering, Vol. 1, Plenum Publishing Corp., N.Y., U.S.A. (1982].) j1~ 1 4 -12- 4444 44 4 444 4444 4)IP 44 4444 4 4444 A preferred method of obtaining the fulllength cloned oDNAs of this invention is the procedure developed by I. Qkayama and P. Berg (Mol. and Coll.
sBiol., 2: 161-170 (19821). This method has the advantage of placing the vDNA inserts in a bacterial cloning vector at a position whereby the McDNA can also be directly translated and processed in mammalian calls. Briefly, the firsat cDNA strand is primed by polydeoxythymidylic acid covalently joined to one end of a linear plamid vector DNA. The plasmid vector is then cyclized with a linker DNA segment that bridges one end of the plasmid to the 5' and of the cDNA coding sequence. By employing a DNA fragment containing the Simian Virus 40 (SV40) early region promoter and a 15 linker containing a modified SV40 late region intron, the eDNA can be expressed in vitro in COS-7 mouse kidney cells without further modification. (See generally Okayama, H. and Berg, Mol. and Ceall., Biol.s, 3: 280- 289 [19831 and Jolly, D. et al., Proc. Nat. Acad. Sci.
SG: 477-481 (19831.) The desired cDNA clones can also be detected and isolated by hybridization screening with appropriate mRNA samples (Heindell, H. et al., Cell, 15: 43-54 [1978]). Altaernatively, the cDNA libraries can be 25 screened by hybrid selection (Harpold, M. atal., Nucleic Acid Res., 5: 2039-2053 [19781 or Farnes, J. t al., Proc. Nat. Acad. Sci. 78: 2253-2257 (1981]) or in Xenopus oocytes (Aurdon, Nature, 233: 177-181 [19711). (See generally Villa-Komaroff, L. at al., Proc. Nat. Acad. Sci. 75: 3727-3731 [1978].) Once the cDNA library in the Okayama/Berg plasmid vector has been completed the cDNA clones are collected, and random pools are checked for the presence of the desired cDNAs by hybrid selection, translation, i .i n:~ r -e .44* Ca 6 4* 4t 4 4 4r 44 4 rtra 1I -13- *Q .9 99 9 9 9i #9 9lP~ .99.
99 9.
*994* and assay by measuring MCGF or multi-CSF growth factor activity, the existence of antigenic determinants, or other biological activities). Pools positive by these criteria can then be probed with an appropriate subtracted probe, CDNA from a B cell line and/or uninduced T cell line. Thereafter, the positive, probed pools are divided into individual clones which are tested by transfection into a suitable host (such as a mammalian cell culture), and the host supernatant assayed for the desired activity (e.g.
multi-CSP or MCGF activity). Positive clones are then sequenced.
In further describing the procedures relating to preparing cDNA clones of the invention, the mast cell 15 and other lines will be considered first, followed by general descriptions of the procedures of the in vitro translation of mRNA coding for a protein exhibiting MCGF activity; the construction of a cDNA library containing the cDNA sequences; hybrid selection of the library; 20 isolation of full-length cDNA clones in a plasmid vector and subsequent expression in mammalian cells; multi-CSF assays; human multi-CSF and MCGF isolation, subcloning and expression in bacteria and yeast; and purification and formulation. A more detailed description of the 25 entire experimental process will follow thereafter.
Mast Cell and T-Cell Lines The preferred cells for use in connection with the present invention are those developed as described by Galli, J. et al. Cell Biol., 95: 435-444 11982]). One cloned mast cell line, designated MC/9 and deposited at the American Type Culture Collection (accession number ATCC CRL 8306) was grown in Dulbecco's modified Eagle's medium (DME) supplemented with i ii 999.9 9 #9 994 9 9 9 99 4 9 99 iS**«t -14supernatants from a ConA-activated T-cell line, designated Cl.Ly 1+2"/9 and deposited at the American Type Culture Collection (Accession Number ATCC CRL 8179) (Nabel, G. et al., Nature, 291: 332-334 (19811). This T-cell line was derived from C57B1/6 mice (Nabel, G. et al., Proc. Natl. Acad. Sci. 78: 1157-1161 11981]), and was maintained in modified supplemental DME (Nabel et al., Cell, 23: 19-28 [19811). It is a suitable mRNA source for the polypeptides of this invention, but other mammalian cell sources (including human peripheral blood) exhibiting the appropriate activity MCGF or multi-CSF) may also be used.
The MC/9 cells are used to assay for MCGF activity, preferably by a 3 H-thymidine incorporation 15 assay according to established methods Nabel et j Nature, 291: 332-334 (1981]). Briefly, MC/9 cells /well) are cultured in flat bottom Falcon microtiter trays in DME supplemented with 4% fetal calf serum, PM 2-mercaptoethanol 2mM glutamine, non- 20 essential amino acids, essential vitamins and varied 644* I concentrations of supernatant in a final volume of 0.1 *l ml. To each culture is added 0.5 Ci 3 H.thymidine for the last 4 hr of a 24 hr incubation period. The cells are then harvested onto glass filters and the 25 radioactivity measured by liquid scintillation spectrometer.
Isolation and size Fractionation of mRNA Total cellular mRNA can be isolated by a variety of well-known methods, by using the guanidinium-thiocyanate extraction procedure of Chirgwin et al. (Biochemistry, 18: 5294-5299 (1979]). If this method is used, approximately 100 Ug of polyA+ mRNA, selected on columns of oligo (dT) cellulose, is obtained from 1-2 x 108 activated helper T-cells, such as Cl.Ly 1+27/9. To fractionate the mRNA by size, 100 Ug of polyA+ mRNA is layered on a 10 ml 5-25% sucrose gradient (10mM Tris'HCl, pH 7.4, 100mM NaCI, 1 mM EDTA), and centrifuged for 19 hr at 26,000 rpm in a Beckman SW41 rotor. 450 Ul fractions are collected and the RNA is precipitated with 2 volumes of ethanol.
Hybrid Selection and Microinjection of Xenopus laevis Oocvtes Filter hybridizations are preferably performed essentially as described by Parnes et al. (Proc. Natl.
Acad. Sci. 78: 2253-2257 [1981]). Aliquots of 44,4 «eluted mRNA are injected into individual Xenopus laevis 15 oocytes by methods well known in the art. Supernatants from viable oocytes are collected after 48 hr, pooled and assayed for activities.
Construction of cDNA Library The cDNA library can best be constructed using the pcDV1 vector-primer and the pLi linker fragment (available from P-L Biochemicals Inc., Milwaukee, WI) according to procedures which result in greatly enriched S1) full-length copies of mRNA transcripts Okayama, H.
and Berg, Mol. Cell Biol., 2, 161-170 [1982] and S 25 Mol. Cell Biol., 3, 280-289 [1983]). The plasmid vector, which contains SV40 early promoter and SV40 RNA processing signals, is designed to promote expression of the cloned cDNA segment in mammalian cells.
Using the Okayama and Berg procedure, the cyclized vector-cDNA preparation is transformed into a competent bacterial cell, such as E. coli MC1061 cells (Casadaban, M. and Cohen, J. Mol. Biol., 138: 179- -16- 207 (19801) using calcium chloride (Cohen, S. ot .,i Proc. Nat. Acad. Sci. 69: 2110-2114 19721).
Starting with 5 Ug of polyA+ RNA from ConA-stimulated Cl.Ly 1+2-/9 cells, about 1.5 x 105 x 6 independent transformants are obtained. About 104 clones are picked up individually and inoculated into wells of microtiter plates (Flow Laboratories Inc., McLean, Virginia) containing 200 1l of L-broth, 50 ug/ml of ampicillin, and 7% DMSO. If desired, sublibraries based on the size of to cDNA insert are prepared from total cDNA library as described by Okayama, H. and Berg, P. (Mol. Cell Biol., with Sall, Clal, and HindliI separately, and electrophoresed in 1% agarose gel. After staining with 15 ethidium bromide, the gel is sliced into 7 sections correspor.aing to cDNA insert sizes of 0 to 1, 1 to 2, 2 to 3, 3 to 4, 4 to 5, 5 to 6, and more than 6 kilobases DNA is extracted from each slice, recyclized with T4 DNA ligase, and used to transform MC1061. All nucleotide sequencing can be performed according to the J procedure of Maxam, A. and Gilbert, W. (Methods Enzymol., 65: 499-560 [19801).
I 4 Preparation of Subtracted cDNA Probe If desired, a 32 P-cDNA probe is enriched for ConA-induced sequence by two cycles of cDNA absorption in order to remove cDNA sequences common between Cl.Ly 1+2-/9 and closely related, but differentiated, cells of the immune system, such as B cell myelomas (see Davis, M. et al., "Isolation of B4 T-Cell Specific Genes", Vitteta, E. and Fox, C. eds., UCLA Symp., pg. 48 [1982)). About 2 vg of mRNA having MCGF or multi-CSF activity from a sucrose gradient fraction is preferably used as template for reverse transcriptase using oligo rl-l_ I -17- (dT) 12-18 primers (available from Collaborative Research, Waltham, Mass.). After hydrolysis of RNA by alkali, 32 P-cDNA is hybridized with 20 Ug of mRNA each from WEHI-231, a B-cell lymphoma (see e.g. Taussig et al., Immunology 39: 57-60 [1980]), and an NS-1-derived hybridoma (ATCC accession number HB-8113) at 680C for 14 hr (cot value=5,000). The unhybridized cDNA is separated from cDNA/RNA hybrids by column chromatography on hydroxyapatite. A second subtraction can then be performed with unhybridized 3 2 P-cDNA using an excess of mRNA (10 Ug) from uninduced Cl.Ly 1+2-/9 cells as above (cot=l,100). The single-stranded 32 P-cDNA enriched for ConA-induced sequences, constituting approximately 1-2% of the starting material, is then used for colony 15 hybridization (Maniatis, T. et al., "Molecular Cloning, A Laboratory Manual", Cold Spring Harbor Laboratory, U.S.A. 11982)).
DNA Transfections into Monkey Cells C1L Approximately Ix10 6 COS-7 monkey kidney cells are seeded onto 60 mm plates the day prior to transfection. Transfections are best performed with Vg of plasmid DNA in 1.5 ml of DME containing 50 mM TrisHC1, pH 7.4, and 400 Vg/ml DEAE-Dextran (Pharmacia -4 Fine Chemicals, Uppsala, Sweden). This solution is then removed after 4 hr and replaced with 2.0 ml DME 4% fetal calf serum. The medium is collected after 72 hr and assayed for MCGF or multi-CSF activity as described above. DNA transfections may be carried out in a variety of other cell sources as well (see below).
-18- Multi-CSF Assays Multi-CSF activity comprises testing for the ability to act on multipotential progenitor cells, or a number of lineage restricted cells, or both. (See generally Iscove, N. et al., J. Cell Physiol. Suppl. 1: 65-78 [1982] and Ruppert, Exp. Hematol. 11: 154-161 (19831.) Basically, the assay conditions allow generation of burst-forming erythroid colonies (BFU-E), granulocyte/macrophage colonies (CFU-G/M) and colonies of mixed lineages (CFU-Mixed) and are performed generally according to the procedures of Metcalf, D. et eal. Cell Physiol., 98: 401-420 j1979]) and Johnson, G. Cell Physiol., 103: 371-383 t1980l).
CSF-c Assay (Colony Forming Unit culture) g Bone marrow cells can be harvested from the femurs of C57BI/6 mice. The cells are washed once and a single-cell suspension prepared in Iscove's modified Dulbecco's Medium, [IMDM] (GIBCO, Grand Island, New York) 3% Fetal Calf Serum [FCS] (GIBCO). The single- 20 cell suspension is plated in plastic tissue-culture dishes and incubated 1-2 hours in a 37°C incubator with 6% CO 2 to allow cells to adhere to the dish. The nonadherent cells are then removed and in some cases placed over a discontinuous Percoll (Sigma Chemical Co., St.
Louis, MO) gradient consisting of 2 ml layers of 40%, I 50%, 60%, 70% Percoll solution (as reported by Kakiuchi Set al., J. Immunol., 131: 109 [19831). The cells at the various interfaces are harvested separately and washed twice with IMDM 3% FCS. (Alternatively, cells not placed over Percoll can be washed once with IMDM 3% FCS.) The separate cell pellets are then resuspended at a concentration of 4.5-6 x 106 cells/ml in IMDM
FCS.
4 iO 4444 4 4..
44 4 .4 4 4 4 .4 I 444* 444* *144 4 4 *14 144 4 -19- CFU-c's can be assayed by using a modification of the methyl-cellulose procedure of Iscove etal (J.
Cell Physiol.t 83: 309 [1974]). FCS (final concentration 2-mercap' 'ethanol (5 x 10-5M), penicillin-stre, .omycin (1:100 of GIBCO stocks), methyl-.cellulose 4000 centipoise), cells (1.5-2 x, 10 5 /ml) and various experimental factors to be tested for CPU-c ability are mixed and 1 ml of the mixture dispensed per small petri dish. The plates are incubated 7 days in a 370C/6% C0 2 incubator. T.ey are then scored for colonies using a dissecting microscope A colony is defined as consisting of 50 or more cells. individual colonies can be extracted, placed on croscope slides, fixed and stained with Wright/Geims 15 (See Todd-Sanfordf Clinical Diagnosis By Laboratory Methods, 15th edition, Davidsohn and. Henry (eds.) 137 (1974]). Morphological analysis of cell types present per single colony is then determined.
BFU-E (Burst Forming Unit Erythroid or CFU-Z) 20 The above procedure is acceptable, with the following modifications. Either at the time of plating in methyl cellulose or 3 days later, sheep erythropoietin (Step III, Connaught Medical Research Laboratories, Philadelphia# PA) is added at a 25 concentration of 0.5-1 unit per plate. Erythroidcontaining colonies (BFU-E or CFU-E) are scored after 10-14 days (from time of plating) as colonies containing visibly read elements. individual colonies are extracted and stained as above for morphological analysis.
44 .4 4 4.4 4 4* 4 4 44.4 4 44.4,4* 4 4 4 4 4 4.4 6 4444 d if -t'MWMM^yi p444 44 44 4 44 44 4
S
4 4 44 ~t 4444 4 4444 4444 4 44*$ *44 4.
44 44 4 44 4. 4 44
S
4.5444 4 4 444444 4 4 44 44 S 44,4 CFU-s (Colony Forming Unit spleen) Bone marrow is extracted from femur bones of C57B1/6 mice. Cells are washed twice with Dulbecco's modified Eagle's medium IDME] (GIBCO) and either injected immediately into the tail vein of lethally irradiated (1000 rads) C57B1/6 recipients or treated further. Treatment consists of the following various procedures: 1) lysis of the cells with anti-e and complement, followed either by immediate injection into recipients, or by culture for various times under various conditions before injection; 2) alternatively, no antiserum lysis is performed, and cells are placed immediately into culture under various conditions. The culture conditions can be as follows: cells are 15 resuspended at 1 x 106 cells/ml in medium consisting of DME (GIBCO) 2-ME (5 x 10- 5 MEM-Vitamins (1:100) (GIBCO), non-essential amino acids (1:100) (GIBCO), Lglutamine (1:100) (GIBCO), penicillin/streptomycin (1:100j (GIBCO), a mix of arginine, asparagine, and 20 folic acid, 15% FCS (GIBCO., 2mM sodium pyruvate various factors to be tested for maintenance of CFU-s (final concentration This cell preparation is then plated in 24 well tissue culture plates (Falcon) at 1 ml/well and incubated in a 37*'/10% CO 2 incubator for various times (minimum of 7 days). Every 3-4 days, nonadherent cells are removed, spun down, resuspended in fresh media containing the appropriate factor, and replated. For assays in which incubation lasted more than 7 days, cells are "moved up" to larger plastic tissue culture vessels in order to maintain all nonadherent cells at a concentration not exceeding 5 x 10 per ml. At the end of incubation, cells are washed twice and resuspended in DME (no supplements) and injected into the tail vein of lethally-irradiated
A
-21- C57B1/6 mice. Cells are injected either at specific viable cell numbers or at specific volume fraction of the culture. Nine to twelve days following injection, spleens are excised and placed in Borin's fixative (Mallinkrodt, St. Louis, MO). Spleen colonies are scored as visible nodules on the spleen surface with the aid of a dissecting microscope (4x).
Human Multi-CSF and MCGF cDNA Isolation DNA clones of rodent genes have been used to identify and isolate DNA encoding the homologous human genes. Because of the relatively low degree of homology S* between human and rodent genes, the stringency of hybridization conditions must be adjusted to allow for cross-hybridization between sequences which are only 15 80% homologous. Several different experimental protocols have been used to achieve this purpose. For example, the human CK immunoglobulin light chain gene has been isolated using the corresponding mouse CK gene as a probe (Heiter, P. et al., Cell 22: 197-207 [1981]) S" 20 and mouse transplantation antigen genes have been i *O isolated by hybridization to DNA clones encoding their human counterparts (Steinnetz, T. et al., Cell 24: 125- '134 [1981]).
A preferred method entails plating Y phage 25 clones from a library of human genomic DNA (Maniatis, T.
et al., "Molecular Cloning, A Laboratory Manual", Cold 4 j Spring Harbor Laboratory, U.S.A. [1982]) at a density of 2 x 104 to 5 x 10 plaques per 150 mm plate on an appropriate host strain, such as E. coli LE392. Ten to twenty plates are generally sufficient.
After 10-12 hours' incubation at 37 0 C, the plates are refrigerated for two hours and then a 132 mm nitrocellulose filter is applied to the agar surface of -22each plate. The filter is allowed to remain in contact with the plate for at least five minutes, during which time the filters are keyed to the plates by puncturing with an ink-filled 22-gauge needle. The filters are then peeled from the plates and incubated successively for at least two minutes first in 250 ml of 0.1 N NaOH, M NaCI; then in 250 ml of 0.5 M Tris'HCl pH 7.5, M NaCI. The filters are dried on paper towels and then baked at 80"C for 4-8 hours.
For hybridization, the filters are wetted in Ix SET (0.15 M NaCI, 30 mM Tris'HCl pH 8.0, 1 mM Na 2 EDTA), then incubated in a solution of 3x SET, Denhardt's (Denhardt, B.B.R.C. 23: 641-646 (19661), 10% dextran sulfate, 0.1% sodium dodecyl 15 sulfate (SDS), and 50 Ug/ml each poly poly (rC), and poly at 65°C for 2 hrs (1.5-2 ml/filter) with constant agitation. This solution is then discarded, and the filters are hybridized with 0.5 Ug 106 cpm) of a nick-translated mouse DNA probe in the same 20 solution (fresh), 1.5-2 ml/filter at 65*C for 1 hour and then at 550C for 12-20 hours. The filters are then washed successively in 3x SET, 1x Denhardt's; 0.1% SDS; Sand 1x SET, 0.1% SDS (10-15 mi/filter) at 55°C for one hour with gentle agitation. The filters are dried on paper towels, then autoradiographed for 12-24 hours with •appropriate film and an intensifying screen.
Hybridizing plaques are pickrd from the agar plates with sterile pasteur pipets, and each is expelled into 1 ml T of 0.1 M NaCl, 0.01 M Tris'HC1 pH 7.5, 10 mm MoC1 2 100 Pg/ml gelatin, with 50 :1 of CHC13 added. After a least 4-8 hours in the cold, the phages from each plaque are rescreened at low density (2000-4000 plaques/150 mm plate) by a procedure identical to that described above.
.1 41 0 -23- In the same manner as described previously in the mouse system, positively-hybridizing phage clones verified by re-screening can then be used as a probe to screen random colonies from a human cDNA library. The human cDNA library should be prepared using RNA from an appropriate cellular source, such as human peripheral blood T lymphocytes (see Gray, P. et al., Nature 295: 503-508 (1972]). Full length cDNA clones can be identified by expression in Cos-7 cells, again as was done for the mouse cDNA clones. The isolated human multi-CSF cDNA clones will be able to express a factor capable of stimulating human bone marrow cells.
9 *r 9 Expression in E. coli, in Yeast and in Cell Culture Prokaryotes, such as E. coli, are very S 15 suitable for expression of the polypeptides of the present invention (rae, for example, U.S. patents number 4,338,397 and 4,411,994), provided that glycosylation is not desired. To obtain high expression levels, promoters should be utilized, such as the 20 (penicillinase) and lactose promoter systems (Chang et al., Nature, 275: 615 [1978]; Itakura et al., Science, 198: 1056 (1977]; Goeddel et al., Nature 281: 544 (1979] or a tryptophan (trp) promoter system (Goeddel et al., .Nucleic Acids Res., 8: 4057 [1980]). These are the most commonly used promoters, but other microbial promoters are available.
Those skilled in the art will realize that not only prokaryotes but also eukaryotic microbes, such as yeast, may also be used in protein production.
Saccharomyces cerevisiae is a preferred eukaryotic microorganism. Suitable promoting sequences in yeast vectors include the promoters for 3-phosphoglycerate kinase (Hitzeman et al., J. Biol. Chem., 255: 2073 _r -24a *ao0 00: a 00 4 0 0~ 0 0 O 0os 0000-~ 01 0e 4 0 0 0: 11980]) or other glycolytic enzymes (Hess et al., J.
Adv. Enzyme Reg., 7: 149 t19681; Holland et al., Biochemistry, 17: 4900 [1978]). Other promoters that have the additional advantage of transcription S controlled by growth conditions may be used. Basically any plasmid vector containing a yeast-compatible promoter, an origin of replication and termination sequences is suitable.
In addition to microorganisms, cell cultures derived from multicellular organisms (especially mammalian cells) may also be used as hosts. Examples of such useful host cell lines are HeLa cells, Chinese hamster ovary cell lines, and baby hamster kidney cell lines. Expression vectors for such cells ordinarily include, as necessary, an origin of replication, a promoter located in front of the gene to be expressed, along with any required ribosome binding sites, RNA splice sites, polyadenylation sites, and transcriptional terminator sequences. When used in mammalian cells, the expression vector often has control functions provided by viral material. For example, commonly used promoters are derived from polyoma, Adenovirus 2, and most frequently SV-40. (See generally U.S.P. 4,399,216, WO 81/02425 and WO 83/03259.) To express cDNA clones of the present invention in E. coli, suitable promoters tr, lac, tac, XpL, etc.) and Shine-Dalgarno sequences will be fused with the entire coding sequence of those plasmids carrying an ATG codon preferably in front of the cleavage site of the signal peptide. More specifically, the cDNA clone of MCGF or multi-CSF, e.g., pcD-MCGF, is first digested with PstI and XhoI endonuclease, and about 1 kb segment containing the entire protein coding sequence is subcloned into the -4^
IL
I
appropriate E. coli expression vectors to express the protein and signal sequence. Alternatively, in order to express only the mature protein, the segment can be subcloned into the PstI and Sail endonuclease sites of 3mp8. Single stranded M13mp8 DNA containing the complementary atrand of protein coding sequence is annealed with a synthetic oligonucleotide GAT ACC CAC CGT TTA and double-stranded protein coding sequence is then synthesized by the Klenow fragment.
After digestion with Neol endonuclease and treatment with Si nuclease, a blunt-ended DNA segment containing the double stranded MCGF coding sequence or multi-CSF coding sequence is inserted into an appropriate 4e expression vector, such as pDR540, which has the tac 15 promoter (see Russel, D.R and Bennett, Gene 231-243 (1982]); and deBoer, H. et al., Proc. Natl.
Acad. Sci. U.S.A. 80, 21-25 (1983]). (See generally Messing, J. et al., Proc. Nat. Acad. Sci. U.S.A. 74, 3642-3646 [1977]); Gronenborn, B. and Messing, J., a.t, 20 Nature 272: 375 119781; Messing, J. et al., Nucl. Acid Res. 9, 309 11981); and Messing, J. and Vieira, Gene 19, 269-276 (19821.) 4 To express an MCGF or multi-CSF cDNA clone in yeast, the PstI-Xhol fragment carrying a CDNA insert is isolated from pcD-MCGF plasmid, and then cloned into the PstI-Sall sites of pUC8. The resultant plasmid B8/pUC8 is cut with PstI and digested with Bal31 to remove the oligo (dG:dC) block placed upstream of the cDNA. An Xhol linker is attached to Bal3l-digested DNA, and the plasmids are recovered in E. coli. The transformants are analysed to determine the size of the deletion. The XhoI-EcoRI fragment (carrying MCGF or multi-CSF cDNA) is then isolated from one of the deletion derivatives, which should have about a 20 base pair deletion, and
I
'1 41 -26- 9# r4 I Ir
IT
a cloned into the HindIII site of pAAH5 and the EcoRI site of pAAR6 by blunt-end ligation using the Klenow fragment. (pUC8 is an M13mp7-derived system useful for insertion mutagenesis and sequencing with synthetic universal primers: See Vieira, J. and Messing, Gene 19: 259-268 11982]); for pcD-X, see Okayama, H. and Berg, Mol. Cell. Biol. 3: 280-289 [19831)I pAAHS and pAAR6 are yeast expression vectors carrying the ADCI promoter and terminator: Ammer, "Expression of Genes in Yeast using the ADCI promoter", Methods in Enzymology, 101: 192-201 [1982].) Purification and Formulations The multi-CSF and MCGF polypeptides expressed in E. coli, in yeast or in other cells can be purified 15 according to standard procedures of the art, including ammonium sulfa'e precipitation, fractionation column chromatography ion exchange, gel filtration, electrophoresis, affinity chromatography, etc.) and ultimately crystallization (see generally "Enzyme 20 purification and Related Techniques", Methods in Enzymology, 22: 233-577 [1977]). Once purified, partially or to homogeneity, the polypeptides of the invention may be used in pharmaceutical compositions (see below), for treating parasitic infections of the gastrointestinal tract; or for research purposes, as a supplement to hematopoietic or mast cell media and as an antigenic substance for eliciting specific immunoglobulins useful in immunoassays, immunofluorescent stainings, etc. (see generally "Immunological Methods", Vols. I II, Eds. Lefkovits, I. and Pernis, Academic Press, New York, N.Y. (1979 1981]; and "Handbook of Experimental Immunology", Ed.
Weir, Blackwell Scientific Publications, St. Louis, MO [1978].) -q I Ia aO a al I Ii art -27- For preparing pharmaceutical compositions containing the polypeptides described by this invention, these polypeptides are compounded by admixture with preferably inert, pharmaceutically acceptable carriers. Suitable carriers and processes fox. their preparation are well known in the art (see e.g.
Remington's Pharmaceutical Sciences and US.
Pharmacopeja: National Formulary, Mack Publishing Company, Easton( PA [19801). The preferred course of administration is parenteral and can include use of mechanical delivery systems.
Preferably~f the pharmaceutical composition is in unit dosage form. in such form, the preparation is subdivided into unit doses containing appropriate quantities of the active component. The quantity of active compound in a unit dose of preparation may be varied or adjusted from I uPg. to 100 mg., according to the particular application and the potency of the active ingredient. The composition can, if desired, also contain other therapeutic agents.
The dosages may be varied depending, upon the requirement of the patient, the severity of the condition being treated and the particular compound being employed. Determination of the proper dosage for U t 25 a particular situation is within the skill of the art.
Generally, treatment is initiated with smaller dosages which are less than the optimum dose of the compound.
Thereafter, the dosage is increased by small increments until the optimum effect under the circumstances is reached. For convenience, the total daily dosage may be *oft divided and administered in portions during the day if desired.
-28- The following experimental information and data are offered by way of example and not by way of limitation.
EXPERIMENTAL
A. Cloned Inducer T Cells 1) A clone ol. T Cells Cl.Ly 12"/9 (ATCC accession number CRL 8179) expressing the Thy 1+ Ly 1+2 phenotype is continuously maintained at 0.5 x 105 cells/ml in Dulbecco's Modified Eagle's medium (DME) with 10% heat-inactivated fetal calf serum, 5 x 10 M 2-ME, 2 mM glutamine, non-essential amino acids, and essential vitamins conditioned with S* jsupernatants from ConA-activated mouse Balb/c spleen cells.
S 15 2) ConA-activation of Cl.Ly 1+2-/9 cells: The i. calls are cultured at 5 x 10 5 /ml in DME with 4% heat-inactivated fetal calf serum, 5 x 10 5 M 2-ME, 2mM glutamine, non-essential amino acids, essential vitamins and 2 ug/ml ConA. After 12-14 hrs.' incubation at 37"C in 10% CO 2 the cell suspension is centrifuged at 1500 rpm for 10 minutes. The cell pellets are collected and frozen immediately at The supernatants are filtered (Nalgene-0.22 microns) and stored at -20'C as a source of growth factors. Aliquots of the supernatant are assayed for MCGF activity (see below) to verify the induction of the line by the ConA treatment.
B. Cloned Mast Cells 1) A mast cell line (MC/9) (ATCC accession number CRL 8306) was cloned by limiting dilution from the a C- 0 -29liver of a 13-day-old mouse fetus in DME with 4% heat-inactivated fetal calf serum (FCS), 5 x 10-5 M 2-ME and 2 mM glutamine conditioned by ConA activated Balb/c spleen cells (Nabel et al., Nature 291: 332-334 [19811). The cell clone expresses the Thy Ly Ly 5 phenotype for surface membrane glycoproteins.
2) The mast cell clone is continuously maintained with doubling times of 16-18 hours in DME with heat-inactivated FCS, 5 x 10 5 M 2-ME and 2 mM glutamine, non-essential amino acids and essential vitamins supplemented with 5% supernatant from ConAactivated inducer T cell clone (see above). The growth of the mast cell clone is dependent on the active growth factor(s) obtained from the supernatant of stimulated Cl.Ly 1+2-/9 cells.
C. Biological Assays for MCGF 1. Tritiated Thymidine Incorporation Assay.
a) 1 x 10 MC/9 cells were cultured in flat-bottom 20 microtiter trays in 0.1 ml of DME with 4% heatinactivated FCS, 5 x 10 5 M 2-ME, 2 mM glutamine, non-essential amino acids, essential o vitamins, and doubling dilutions of test supernatant.
25 b) The trays were incubated at 37*C in 10% CO 2 After twenty hours, 0.5 uCi 3 H-thymidine (New England Nuclear, Boston, Mass.) was added to each culture. Four hours later, the cells were harvested onto filter paper strips, using an 30 automated cell harvester unit. The dried samples were dispensed into liquid scintillation fluid and the cpm were counted in a standard counter.
-7 4 i :i i 4* 4r*4 444,r 4tr~ 4*44 4 4* *4 4 4 4r 4 1 2. Tetrazolium Salt (MTT) Colorimetric Assay.
a) 1 x 104 MC/9 cells were cultured in flat-bottom microtiter trays in 0.1 ml of DME supplemented with co-factors and test supernatant as described in 1) a).
b) The trays were incubated at 37*C in 10% CO 2 After twenty hours, 0.01 ml of 5 mg/ml MTT dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide, Sigma Chemical Co., St. Louis, MO) in phosphate-buffered saline (PBS) was added to each culture. Four hours later 0.1 ml of 0.04 N HC1 in isopropanol was added to each culture and thoroughly mixed. After a few minutes, the plates were read on a Dynatech MR580 Microelisa Auto Reader (Dynatech Instruments, Inc., Torrance, CA), at a wavelength of 570 nm (reference wavelength of 630nm) and a calibration setting of 1.99.
D. Isolation of mRNA from Cl.Ly 1+279- cells.
1. Total cellular RNA was isolated from cells using the guanidine isothiocyanate procedure of Chirgwin et al. (Biochemistry, 18: 5294-5299 [1979]).
Frozen cell pellets from uninduced or ConAinduced C1.Ly I12-/9 were suspended in guanidine isothiocyanate lysis solution. Twenty ml of lysis solution was used for 1-2 x 108 cells. Pellets were resuspended by pipetting, then DNA was sheared by 4 passes through a syringe using a 16 gauge needle.
The lysate was layered on top of 20 ml of 5.7 M CsCI, 10 mM EDTA in 40 ml polyallomer centrifuge tube.
This solution was centrifuged at 25,000 rpm in a Beckman SW28 rotor (Beckman Instruments, Inc., Palo Alto, CA) for 40 hrs at 15*C. The guanidine isothiocyanate phase containing DNA was pipetted off r4 44 4 *444: -31from the top, down to the interface. The walls of the tube and interface were washed with 2-3 ml of guanidine isothiocyanate lysis solution. The tube was cut below the interface with scissors, and the CsCI solution was decanted. RNA pellets were washed twice with cold 70% ethanol. Pellets were then resuspended in 500 ul of 10 mM Tris'HCl pH 7.4, 1 mM EDTA, 0.05% SDS. 50 i1 of 3M sodium acetate was added and RNA was precipitated with 1 ml ethanol.
The RNA was collected by centrifuging and the pellets washed once with cold ethanol.
2) Poly A+ mRNA isolation: Washed and dried total RNA pellet was resuspended in 900 P1 of oligo (dT) elution buffer (10 mM Tris'HCl, pH 7.4, 1 mM EDTA, 0.5% SDS). RNA was heated for 3 min. at 68°C and then chilled on ice.
100 V1 of 5 M NaCl was added. The RNA sample was r loaded onto a 1.0 ml oligo (dT) cellulose column (Type 3, Collaborative Research, Waltham, MA) S 20 equilibrated with binding buffer (10 mM Tris'HCl pH 7.4, 1 mM EDTA, 0.5 M NaCl, 0.5% SDS.). Flow-through from the column was passed over the column twice more. The column was then washed with 20 ml binding buffer. Poly A+ mRNA was collected by washing with 25 elution buffer. RNA usually eluted in the first 2 ml of elution buffer. RNA was precipitated with 0.1 volume 3 M sodium acetate (pH 6) and two volumes of S ethanol. The RNA pellet was collected by S, *centrifugation, washed twice with cold ethanol, and 30 dried. The pellet was then resuspended in water.
Aliquots were diluted, and absorbance at 260 nm was determined.
IL
t 4 1. -32-
A
*4 *0 *0 0 0 *0*0
I
*0*0 *000 0 6000 0 000 0*
I
66 4 44 I I It E. Fractionation of poly A+ mRNA by Sucrose Gradient Centrifugation: 100 Vi containing 100 Vg of poly A+ mRNA from D.
2) was heated at 65°C for 1 min. and then layered onto a 10 ml 5-25% sucrose gradient (10 mM Tris'HCl pH 7.4, 100 mM NaCI, and 1 mM EDTA). The gradient was centrifuged in a Beckman SW41 rotor at 26,000 rpm for 19 hours at 5°C. 450 Vl fractions were collected, precipitated with 2 volumes of ethanol and resuspended for injection into oocytes (see below).
A parallel gradient was layered with a mixture of radio-labelled 3 H-uridine) ribosomal RNA (BRL, Bethesda, MA) centrifuged as described above, and 450 Pi fractions were counted in the scintillation counter.
The size-fractionated Poly A+ mRNA, following injection in Xenopus oocytes, gave a peak of MCGF activity by the colorimetric assay sedimenting slower than 18S, as shown in Figure 2. These fractions were enriched approximately 10-fold for MCGF mRNA and were utilized subsequently for the preparation of 32p_ labelled cDNA probe.
F. Oocyte Injection Oocytes were removed from female Xenopus laevis and incubated in Barth's solution (88 mM NaCl, 1 mM KC1, 0.33 mM Ca(N0 3 2 0.41 mM CaCI 2 0.82 mM MgSO 4 2.4 mM NaHCO 3 10 mM HEPES (pH 7.9) (Sigma Chemical Co., St. Louis, MO). Injection clusters of 2-3 oocytes were prepared. RNA samples were to be injected dissolved in injection buffer (40 mM Tris'HCl pH 7.4, 0.35 M NaCI). Total poly A+ mRNA was resuspended at a concentration of 500 Ug/ml in injection buffer, while RNA samples eluted from DNA 1060*4
I
I
4 0 .6* II 4 0144 -33filters from hybrid selections (see below) always contained 5 Ug of calf liver tRNA as carrier and were resuspended in 2 U1 of injection buffer. 40 nl aliquots were injected into each oocyte using micropipets pulled by hand with tips forged using a microforge. The pipettes were calibrated with known volumes of sterile water. Approximately 30-40 oocytes were injected for each mRNA sample. The injected oocytes were incubated in groups of two or three in individual wells of 96-well microtiter dishes containing 10 vl of Barth's solution 1% bovine serum albumin per oocyte. The oocytes were kept at 19*C for 48 hours and then the supernatants from wells containing viable oocytes were collected and pooled. These supernatants were sterilized by centrifuging for 10 minutes in a microcentrifuge and then assayed for MCGF activity as described above.
Supernatants from uninjected oocytes were always collected as a control.
20 The assay results from supernatants collected from untreated or ConA-stimulated Cl.Ly 1+2-/9 cells are shown in Table I. Titration of all samples, including the reference standard, was performed in triplicate. One unit of MCGF is the amount of factor that results in 25 of the maximal level of 3 H-thymidine incorporation obtained using Cl.Ly 1+2-/9 supernatant.
TABLE I Cl.Ly 1+2-/9-Produced MCGF Activity (units/ml) 4S *4* w* *444 9Ct *4* *44 *J .4 .4 9i 9 I$4 &i ,t
I.
4*14 Cell Supernatant Injected mRNA without ConA with ConA 26,383 1 ,403 -34- G. cDNA Library Construction: 1) Preparation of vector primer and oligo dG-tailed linker DNAs: The procedure of Okayama Berg (Mol. Cell.
Biol. 2: 161-170 (1982]) was used with only minor modifications and adapted to the pcDV1 and pL1 plasmids described by Okayama Berg (Mol. Cell.
Biol. 3: 380-389 (1983)].
An 80 Pg sample of pcDV1 DNA was digested at with 20 U of KpnI endonuclease in a reaction mixture of 450 P1 containing 6 mM Tris'HCl (pH 6 mM MgC1 2 6 mM NaCl, 6 mM 2-ME, and 0.1 mg of bovine serum albumin (BSA) per ml. After 16 hr the digestion was terminated with 40 ul of 0.25 M EDTA q 15 (pH 8.0) and 20 V1 of 10% sodium dodecyl sulfate (SDS); the DNA was recovered after extraction with water-saturated 1:1 phenol-CHCl 3 (hereafter referred to as phenol-CHCl 3 and ethanol precipitation.
Homopolymer tails averaging 60, but not more than deoxythymidylate (dT) residues per end were added to the KpnI endonuclease-generated termini with calf thymus terminal transferase as follows: The reaction mixture (38 V1) contained sodium cacodylate-30 mM Tris'HCl pH 6.8 as buffer, with 1 mM CoC1 2 0.1 mM dithiothreitol, 0.25 mM dTTP, the KpnI endonucleasedigested DNA, and 68 U of the terminal deoxynucleotidyl transferase (P-L Biochemicals, Inc., I tv* Milwaukee, WI). After 30 min. at 37 0 C the reaction was stopped with 20 V1 of 0.25 M EDTA (pH 8.0) and U1 of 10% SDS, and the DNA was recovered after several extractions with phenol-CHCl 3 by ethanol precipitation. The DNA was then digested with 15 U of EcoRI endonuclease in 50 VI containing 10 mM Tris'HCl pH 7.4, 10 mM MgCl2, 1 mM dithiothreitol, and 0.1 mg of BSA per ml for 5 hr at 37°C. The large fragment, containing the SV40 polyadenylation site and the pBR322 origin of replication and ampicillinresistance gene, was purified by agarose gel electrophoresis and recovered from the gel by a modification of the glass powder method (Vogelstein, B. Gillespie, Proc. Nat. Acad. Sci. 76: 615-619 [1979]). The dT-tailed DNA was further purified by absorption and elution from an oligo (dA)-cellulose column as follows: The DNA was dissolved in 1 ml of mM Tris'HCl pH 7.3 buffer containing 1 mM EDTA and 1 M NaCl, cooled at 0 C, and applied to an oligo a (dA)-cellulose column (0.6 by 2.5 cm) equilibrated with the same buffer at 0°C. The column was washed with the same buffer at 0 C and eluted with water at room temperature. The eluted DNA was precipitate with ethanol and dissolved in 10 mM Tris'HCl pH 7.3 with 1 mM EDTA.
The oligo (dG) tailed linker DNA was prepared by digesting 75 Pg of pL1 DNA with 20 U of PstI :endonuclease in 450 UI containing 6 mM Tris'HCl pH 25 7.4, 6 mM MgCl 2 6 mM 2-ME, 50 mM NaCl, and 0.01 mg of BSA per ml. After 16 hr at 30 C the reaction .I mixture was extracted with phenol-CHC1 3 and the DNA Swas precipitated with alcohol. Tails of 10 to deoxyguanylate (dG) residues were then added per end 0 30 with 46 U of terminal deoxynucleotidyl transferase in 4 bu the same reaction mixture (38 111) as described above, except that 0.1 mM dGTP replaced dTTP. After 20 min.
at 37°C the mixture was extracted with phenol-CHCl 3 and after the DNA was precipitated with ethanol it was digested with 35 U of HindII endonuclease in -36-
I
4~ ot I i
P
4 44 i 4*4 4 1 4 II Ui containing 20 mM Tris'HCl pH 7.4, 7 mM MgC1 2 mM NaCI, and 0.1 mg of BSA at 37°C for 4 hr. The small oligo (dG)-tailed linker DNA was purified by agarose gel electrophoresis and recovered as described above.
2) cDNA Library Preparation: Step 1. cDNA synthesis.
The reaction mixture (10 P1) contained 50 mM Tris'HCl pH 8.3, 8 mM MgC1 2 30 mM KC1, 0.3 mM dithiothreitol, 2 mM each dATP, dTTP, dGTP, and dCTP, PCi 3 2 P-dCTP (3000 Ci/mmole), 2 Pg polyA RNA from Con-A induced Cl.Ly 60 units RNase (Biotec, Inc., Madison, WI), and 2 ug of the vector-primer DNA pmol of primer end), and 45 U of reverse transcriptase. The reaction was incubated 60 min at 42"C and then stopped by the addition of 1 P1 of 0.25 M ETDA (pH 8.0) and 0.5 P1 of 10% SDS; 40 P1 of phenol-CHCl 3 was added, and the solution was blended vigorously in a Vortex mixer and then centrifuged.
After adding 40 P1 of 4 M ammonium acetate and 160 1l of ethanol to the aqueous phase, the solution was chilled with dry ice for 15 min., warmed to room temperature with gentle shaking to dissolve unreacted deoxynucleoside triphosphates that had precipitated during chilling, and centrifuged for 10 min. in an Eppendorf microfuge. The pellet was dissolved in ul of 10mM Tris'HCl pH 7.3 and 1 mM EDTA, mixed with ul of 4 M ammonium acetate, and reprecipitated with 40 pl of ethanol, a procedure which removes more than 99% of unreacted deoxynucleoside triphosphates. The pellet was rinsed with ethanol.
1" I Z -37a.,r *r 0 *0*I QW44 Step 2: Oligodeoxycytidylate [oligo (dC)] addition.
The pellet containing the plasmid-cDNA:mRNA was dissolved in 20 11 of 140 mM sodium cacodylate-30 mM Tris'HCl pH 6.8 buffer containing 1 mM CoC1 2 0.1 mM dithiothreitol, 0.2 Og of poly(A), 70 PM dCTP, 5 PCi 3 2 P-dCTP, 3000 Ci/mmole, and 60 U of terminal deoxynucleotidyl transferase. The reaction was carried out at 37*C for 5 min. to permit the addition of 10 to 15 residues of dCMP per end and then terminated with 2 P1 of 0.25 M EDTA (pH 8.0) and 1 P2 of 10% SDS. After extraction with 20 11 of phenol- CHC1 3 the aqueous phase was mixed with 20 21 of 4 M ammonium acetate, the DNA was precipitated and reprecipitated with 80 11 of ethanol, and the final pellet was rinsed with ethanol.
Step 3: HindIII endonuclease digestion.
The pellet was dissolved in 30 U: of buffer containing 20 mM Tris'HCl pH 7.4, 7 mM MgC1 2 60 mM NaCI, and 0.1 mg of BSA per ml and then digested with 10 U of HindIII endonuclease for 2 hr at 37°C. The reaction was terminated with 3 P1 of 0.25 M EDTA (pH 8.0) and 1.5 PI of 10% SDS and, after extraction with phenol-CHCl 3 followed by the addition of 30 21 of 4 M ammonium acetate, the DNA was precipitated with 120 21 of ethanol. The pellet was rinsed with ethanol and then dissolved in 10 21 of 10 mM Tris'HCl (pH 7.3) and 1 mM EDTA, and 3 ~i of ethanol was added to prevent freezing during storage at Step 4: Cyclization mediated by the oligo (dG)-tailed linker DNA.
A 9 2i sample of the HindIII endonuclease-digested oligo (dC)-tailed cDNA:mRNA plasmid (90% of the aa 4r
U.
a ar
U
ai -38- 4 4 4 I* 4 4444 **44 t o4 o 4.
44 o* 4 *4 4 44*44 S& 4 *f 4 44< o 4 4 44* sample) was incubated in a mixture (90 1l) containing 10 mM Tris'HCl pH 7.5, 1 mM EDTA, 0.1 M NaCI, and 1.8 pmol of the oligo (dG)-tailed linker DNA at for 5 min, shifted to 42"C for 60 min, and then cooled to 0°C. The mixture (90 Ul) was adjusted to a volume of 900 P1 containing 20 mM Tris'HCl pH 7.5, 4 mM MgC1 2 10 mM (NH 4 2
SO
4 0.1 M KC1, 50 Pg of BSA per ml, and 0.1 mM B-NAD; 6Ug of E. coli DNA ligase were added and the solution was then incubated overnight at 12'C.
Step 5: Replacement of RNA strand by DNA.
To replace the RNA strand of the insert, the ligation mixture was adjusted to contain 40 VM of each of the four deoxynucleoside triphosphates, 0.15 mM B-NAD, 4 Pg of additional E. coli DNA ligase, 16 U of E. coli DNA polymerase I (Poll,) and 9 U of E. coli RNase H. This mixture (960 Pi) was incubated successively at 12°C and room temperature for 1 hr each to promote optimal repair synthesis and nick translation by Poll.
Step 6: Transformation of E. coli.
Transformation was carried out using minor modifications of the procedure described by Cohen et al. (Proc. Nat. Acad. Sci. 69: 2110-2114 [1972]). E. coli K-12 strain MC1061 (Casadaban, M.
and Cohen, J. Mol. Biol. 138: 179-207 [1980]) was grown to 0.5 absorbancy unit at 600 nm at 37°C in ml of L-broth. The cells wete collected by centrifugation, suspended in 10 ml of 10 mM Tris'HCl pH 7.3 containing 50 mM CaC1 2 and centrifuged at 0 C for 5 min. The cells were resuspended in 2 ml of the above buffer and incubated again at 0"C for 5 min.; then, 0.2 ml of the cell suspensions was mixed with 0.1 ml of the DNA solution (step 5) and incubated at -39- 0OC for 15 min. Next the cells were kept at 37*C for 2 min. and thereafter at room temperature for min.; then 0.5 ml of L-broth was added, and the culture was incubated at 37'C for 30 min., mixed with 2.5 ml of L-broth soft agar at 42°C, and spread over L-broth agar containing 50 Vg of ampicillin per ml.
After incubation at 37°C for 12 to 24 hr, individual colonies were picked with sterile tooth-picks.
Approximately 1 x 106 independent cDNA clones were generated and, of these, 10,000 clones were picked up individually and inoculated into wells of microtiter plates containing 200 I~ of L-broth, 50 Vg/ml ampicillin, and 7% DMSO. Random pools of approximately 1000 clones each were generated, and 15 plasmid DNA prepared for hybrid selection experiments.
rrs4 H. Hybrid selections.
Hybrid selections were performed with eight cDNA plasmid preparations, taken from the random pools 20 described above.
1) Preparation of DNA filters All plasmid DNAs were linearized by digestion with Clal prior to binding to nitrocellulose S i filters. Digestions vere performed in 50 V1 25 containing: 10 mM Tris'HC1 pH 7.9, 10 mM MgC1 2 lg plasmid DNA, 50 mM NaC1, and 10 units Clal.
Following a 2 hr incubation at 37°C, samples were diluted to 200 1u with TE (10 mM Tris'HCl pH 8.0, 1 mM EDTA) and extracted with an equal volume (200 vl) of phenol saturated with TE. 20 V1 of 3M sodium acetate (pH 6) was added to the aqueous phase, and this was precipitated with 2 volumes of ethanol. The DNA pellets were recovered by centrifugation and then hi 0 ~q.
~q# I I *1*1*1
I
t I.
washed with 70% ethanol. The dried pellet was resuspended in 150 PI of sterile water for each 10 Ul of DNA. Duplicate filters were prepared for each DNA sample, 10 Ug DNA per filter. The DNA in 150 Ul of water was boiled for 10 min, then 150 Ul IN NaOH was added and the solution incubated 20 rmin at room temperature. The sample was chilled on ice, then 150 PUl 1M HC1, IM NaCI, 0.3M Na-citrate and Tris'HCl pH 8.0 was added.
0.9 cm Millipore HAWP filters wet with distilled water were fitted into Schleicher-and-Schuell microfiltration apparatus. The denatured and neutralized DNA solution from above was filtered through by centrifugation at 500 rpm for 5 min.
Filters were washed with 1 ml of 6xSSC (0.15 M NaCI, 0.015 M Na citrate) and then air-dried before baking 2 hrs. at 80 0
C.
2) Hybridizations Hybridizations were performed in 200 PI containing 65% redistilled formamide, 20 mM PIPES, pH 6.4, 0.4 M NaC1, 200 Vg/ml calf liver tRNA, and 100 ug/ml polyA+ mRNA from ConA-induced Cl.Ly Each hybridization solution was heated for 3 min at 70°C and then two DNA filters (10 Pg DNA/filter) were cut into quarters and added to the solution. Hybrids were incubated at 50°C for 4 hours followed by 4 hour incubations at 46" and 42*C.
After this period the supernatants were removed and the filters washed 3 times with 1 ml of: 10 mM Tris'HCl pH 7.4, 0.15M NaCI, 1 mM EDTA, 0.5% SDS.
This was followed by three 1 ml washes with the same buffer lacking SDS. Both buffers were kept at for the washes. To elute the hybridized mRNA, 400 vI of distilled water with 5 Vg calf liver tRNA was -jL, i
I
S
i I -41- 444 4 44i 4 4
**C
*9 4*44 9ra 4 *9 44 44 added to the vial with the filters. The tubes were boiled for 3 min and then quick chilled in dry ice/ethanol. Samples were thawed and the eluted RNA precipitated with 2 volumes of ethanol and 0.1 volume 3M Na acetate (pH RNA pellets were collected by centrifugation and washed twice with 70% ethanol.
The dried pellets were resuspended in 2 ui of oocyte injection buffer and the entire sample was injected into oocytes (see above).
Of 8 initial pools which were screened in this manner, several were positive, and one pool showing the highest level of MCGF activity was chosen for further analysis. This pool, which consisted of 672 individual clones, was subdivided further into 14 sub-pools of 48 clones each. Plasmid DNA from these sub-pools was used in a second series of hybrid selections. Only one of these sub-pools gave a positive signal. The 48 clones were then screened with the two subtracted cDNA probes as described below.
Preparation of Subtracted cDNA Probe 32 P-cDNA synthesis: 2 Vg of polyA mRNA from the MCGF peak fraction of the sucrose gradient from above was resuspended in 2 P1 of water. This was heated for 5 min at then added to a reaction containing 50 mM Tris'HCl pH 8.3, 8 mM MgC! 2 30 mM KC1, 0.7 mM DTT, 1 mM each of dATP, dGTP and dTTP, 34 PM dCTP, 10 Ug/ml oligo-(12- 18]-(dT) (Collaborative Research), 100 ug/ml Actinomycin D, 500 PCi a 3 2 p-dCTP (Amersham, 3000 Ci/mmole) and 150 units reverse transcriptase (Life Sciences, Inc., St. Petersburg, FL) in a total volume of 100 V1. Following a 2 hr incubation at 40 0 C, i 9 9 *49 jj i L, ir -42- ~l of the reaction was removed for precipitation in trichloroacetic acid to determine the amount of 32p incorporated. Then, 100 V~ of 0.2 N NaOH was added, and the sample was heated 20 min at 70 0 C to hydrolyze the RNA. After cooling, the reaction was neutralized with 20 Ui of 1 N HC1, and 4 i1 of 1 mg/ml tRNA was added as carrier. The sample was extracted twice with an equal volume of phenol-chloroform It was then precipitated with an equal volume of 4 M ammonium acetate and 2 volumes of ethanol. The pellet was resuspended in 100 111 water, the precipitation repeated, and the pellet washed twice I I with 80% ethanol.
2) First subtractive hybridization: 15 32 P-cDNA (synthesized as described above) was co-precipitated with 20 vg of polyA mRNA from WEHI-3 and 20 1I of poly A+ mRNA from a B-cell hybridoma. The pellet was resuspended in 7 P1 water, 1 Pi 4 M Na phosphate pH 7, 0.1 ,l 20% SDS, 20 and 0.1 V1 0.1M EDTA, and then the entire sample was sealed in a capillary tube. The sample was V" heated 30 min at 90'C, then shifted to 68'C for 14 hrs (Cot 5000). The hybridization mixture was S""then diluted to 1 ml with 0.12 M sodium phosphate 25 pH 7.0 and 0.1% SDS, and the temperature of the mixture raised to 60°C. The mixture was then loaded on a column of 0.4 gm hydroxyapatite equili- ;Ao brated in the same buffer and kept at 60°C. The flowthrough was collected and the column was then washed with 5 ml of the same buffer at 60 0 C. 1 ml fractions were collected and 1 Vi aliquots of each fraction were counted in a scintillation counter.
The peak of single stranded cDNA in fractions 2, 3, and 4 was pooled. This material, representing -43- 66.5% of the starting 32 P-cDNA, was concentrated to 0.4 ml by extraction with 2-butanol and then desalted by chromatography on a 2 ml Sephadex column.
3) Second subtractive hybridization: The desalted sample from above was concentrated by ethanol precipitation and then co-precipitated with 9.5 Ig of poly A mRNA from uninduced Cl.Ly 1+2 The washed and dried pellet was resuspended in 10 1l water, 1.5 1 4M sodium phosphate pH 7, 0.15 P1 20% SDS and 0.15 ul 0.1 M EDTA. The sample was incubated in a sealed capillary tube for 30 min at 90°C and then at 68°C for 20 hr. Chromatography on hydroxyapatite was 15 repeated as described above. The single stranded cDNA which eluted from the column at represented 17% of the starting material. This 32 P-cDNA was used for colony hybridizations of the 48 colonies in the sub-pool identified by hybrid 20 selections. Three colonies hybridized with the probe and were used for further hybrid selection.
T One of these, designated clone 5G, was reproducibly positive.
J. Size fractionated sub-library 30 Vg of plasmid DNA representing the entire cDNA library (pcD-X DNA) was digested separately with the restriction enxymes SalI, HindIII, and ClaI to linearize the plasmid. The restricted DNAs were size-fractionated on a 1% agarose gel to separate plasmids having different size cDNA inserts. Segments were excised from the gel representing plasmids with cDNA inserts of the following size ranges: -44- 0 1kb 1 2kb 3 4kb 4 5 6kb 6 kb and longer DNA was eluted from each gel slice using the glass powder method of Vogelstein and Gillespie (Proc. Nat. Acad. Sci. 76: 615-619 10 [1970]). The eluted DNAs from the 3 digests were pooled on the basis of size, and treated with T4 ligase to recyclize in a total volume of 15 il containing 50 mM Tris*HCl pH 7.4, 10 mM MgC12, mM DTT, 1 mM spermidine, 1 mM ATP and 100 Ug/ml BSA. The ligation reactions were incubated 16 hr at 12*C. 3 Pl of each combined size fraction was used to transform E. coli strain MC 1061 using the I method of Cohen et al. (Proc. Nat. Acad. Sci.
rU.S.A., 69: 2110-2114 [1972]). A library of 1.1 x 105 independent transformations was obtained for the fraction containing cDNA inserts 1-2 kb in S'length, which was used for subsequent screening for S full-length MCGF clones.
K. Screening of Size-fractionated Sub-library f 25 Preliminary restriction endonuclease analysis, as well as DNA sequence data, indicated that the cDNA insert for clone 5G (identified bN hybrid selection) was approximately 650 base pairs long.
An internal BamH1-NcoI restriction fragment was isolated from clone 5G. The fragment was dephosphorylated with calf intestinal alkaline phosphatase according to the method of Chacomas, G.
and Sande, J. (Methods Enzymol. 65: 75-79 119801). The fragment was then labelled using
Y
32 P-ATP and T4 polynucleotide kinase according to the method of Maxam, A. and Gilbert, W. (Methods Enzymol. 65: 499-507 [1980)). This labelled fragment was then used to probe an RNA blot of ConA-induced Cl.Ly 1+2-/9 mRNA. A single band, approximately 1 kb long, was detected, suggesting that clone 5G was not a full-length clone.
1 We therefore used the same probe from the S" cDNA insert to screen the sub-library enriched for 1-2 kb inserts (from above). We employed the 15 method of Hanahan and Moselson (Gene, 10: 63 [1980]) as described by Maniatis, T. et al.
(Molecular Chem., Cold Spring Harbor Laboratory [19821). Approximately 500-1000 bacteria were spread on 80 mm nitrocellulose filters and o 20 incubated on L-broth plates containing 50 Ui/ml ampicillin at 37 0 C, and the bacterial colonies transferred to a second nitrocellulose filter. The duplicate filters were incubated on L-broth «ampicillin for 8 hrs. at 37°C, transferred to L- S° 25 broth plates containing 10 Ig/ml chloramphenicol and incubated overnight to amplify the copy number of the plasmid. The DNA from the colonies was bound to the nitrocellulose following lysis of the colonies with SDS, denaturation with NaOH and neutralization as described by Maniatis, T. et al., supra.
Approximately 20,000 colonies were screened and 19 colonies were reproducibly positive following rescreening with the probe. Plasmid DNA from these -46colonies was prepared and used in transfection experiments.
L. DNA Transfections One day prior to transfection, approximately 106 COS-7 monkey cells were seeded onto individual mm plates in DME containing 10% fetal calf serum and 2 M glutamine. To perform the transfection, the medium was aspirated from each plate and replaced with 1.5 ml of DME containing 50 mM Tris'HCl pH 7.4, 400 Vg/ml DEAE-Dextran and 15 Pg of the plasmid DNAs to be tested. The plates were incubated for four hours at 37"C, then the DNAcontaining medium was removed, and the plates were washed twice with 2 ml of serum-free DME. 2.0 ml 15 of DME containing 4% fetal calf serum and 2 mM glutamine was added to the plates, which were then incubated 72 hours at 37"C. The growth medium was rPa collected and assayed for MCGF activity as Sdescribed above.
Five of the six initial positive clones were examined by transfection and the results are shown Sin Table II. Mock infected COS-7 cells were treated identically, but omitting DNA.
t I y 0
_I
It -47- TABLE II Transient Expression of MCGF in Monkey Cells Length cDNA of Oligo(dG) MCGF Activity Clone Start Point* Block*** in units/ml Mock B4 41 13 5,228 Br ND** ND 7,371 B6 1 13 3,307 B8 1 13 6,929 B9 1 13 3,362 Cl.Ly 1+2-/9 19,769 S* The 5' end of MCGF cDNA expressed as nucleotide t* residue in Fig. 1.
15 Not determined; cDNA start point is located at the o. side of position 41.
Oligo (dG) block at the 5' end of MCGF cDNA.
A plasmid (pcD-MCGF) carrying a full-length SMCGF and multi-CSF (see below) cDNA insert is shown in 20 Figure 3, and an E. coli bacterium carrying the plasmid t has been deposited with the ATCC (accession number S39467). The 950 bp insert is contained in the pcD i expression vector. Transcription from the SV40 early S( promoter is indicated by the arrow. The location of T 25 the splice donor and acceptor sites are shown. The polyadenylation signal, also derived from SV40, is located at the 3' end of the cDNA insert. The cDNA insert is heavily shaded. The remainder of the vector sequences are derived from pBR322 including the Blactamase gene (AmpR) and the origin of replication.
-q -48- Figure 4 shows the restriction endonuclease cleavage map of the cDNA insert of the present invention, and Figure 1 contains the nucleotide sequence and putative amino acid sequence.
Three cDNA inserts contain a single open reading frame consisting of 166 codons beginning with the methionine codon at position 28. In addition to this putative initiation codon, two other methionine codons occur, 12 and 18 codons downstream from the first. A fourth cDNA clone starts 40 base pairs downstream from the 5' ends of the other three inserts. This shorter cDNA clone lacks the first methionine codon but still makes active MCGF upon introduction into COS cells. Thus, one of the two ATG 15 codons downstream can apparently serve as the initiation codon.
"Clone B9 expressed in COS-7 cells (COS-MCGF) Swas used to evaluate, in the absence of other T cell products, its spectrum of activities. The expressed material is not mitogenic for T or B cells, fails to induce immunoglobulin production by B cells (Table III), and does not induce macrophage la expression.
:However, this gene product does stimulate the formation of hematopoietic colonies in bone marrow cells suspended in methylcellulose, demonstrating that a S"single gene product can exhibit both MCGF and colony stimulating activities.
II
W s 4 *4 Cty a 4 4~ 8 n* TABLE ITT. cXS-MCGF stimulates BR-W-E, CFU-C and CFU-mixed in mthylcellulose bone marrow cultures Supernatant Non- TCGF** BCGFt PFCtt added to erythroid CFU- Activity Activity culture Expt. CFU-C* BRU-E* Mixed* Units/il Units/il (106 B cells) COS-7 cells transfected 1 263 25.5 5.3 1.7 12.7 1.2 0 0 with CGF cNA 2 224 17.6 3.3 2 4.3A: 1.1 MOCK transfected 1 0 0 0 0 0 33 COS-7 cells 2 1.7 0.6 0 0 L cells 1 304 25.2 0 0 ND ND ND Cl.r y 1'2-/9 1 404 -1 23.0 5.0 -1 1.2 18.0 2.1 3,250 512 4,560 Medium 1 0 0 0 0 0 6 ND not determined. N, t, tt :For these footnotes, see next paqe.
I Im 0 Notes from Table III Number of colonies per 1.5 x 105 bone marrow cells.
Each value represents mean SEM of colonies determined from triplicate cultures. 1.5 x 10 5 nonadherent, light density (<1.077 g/ml) bone marrow cells from C57B1/6 mice were suspended in 1 ml aliquots in 35 mm dishes containing 0.9% methylcellulose, 20% FCS, Iscove's modified Dulbecco's medium, 50 IM 2-ME, and 30% medium conditioned by cell supernatants as indicated. Mouse L cells were used as a source of CSF, which induces the formation O~oof macrophage colonies. Following 5 days of ~incubation at 37°C in CO 2 0.5 1.0 unit of erythropoietin (Connaught step III) was added to each 15 plate. After incubating the plates for an additional 0 0 7 days, the colonies were counted using a dissecting microscope.
TCGF activity was assayed as previously described.
One unit of TCGF activity is defined as that amount S 20 which causes 25% of the maximum level of 3H-thymidine I aJ. incorporation in 5 x 103 HT-2 cells.
o ao° °t B cells were purified from spleen cells of C57B1/6 mice and assayed for proliferation as described. One unit of BCGF activity is defined as that amount which causes 50% of the level of 3 H-thymidine incorporation in 1 x 105 B cells stimulated by 2 Pg/ml
LPS.
tt Total immunoglobulin-secreting plaque-forming cells were enumerated by a modification of che hemolytic plaque assay.
A
-51- Specifically, the expressed B-9 clone was tested under conditions which allow generation of BFU- E, CFU-G/M and CFU-Mixed. Table III shows that three types of colonies could be identified and enumerated in cultures of bone marrow cells incubated with the expressed material. The most prevalent type consisted of colorless colonies lacking hemoglobinized elements Their morphology was typical of granulocyte/macrophage colonies, the existence of which was later confirmed by histochemical staining. Also present were some large macroscopic colonies containing a multicentric arrangement of uniformly red cell clusters, which were designated BFU-E. We further S. observed a few colonies containing hemoglobinized cells 15 mixed with large and small translucent cells, which were counted as mixed.
The composition of these various colonies was analyzed by applying selected colonies to glass slides o and staining with Wright-Giemsa or nonspecific esterase stains. Over 300 colonies were examined. The majority of these colonies were composed of granulocytes, macrophages or a granulocyte/macrophage mixture, while o four percent consisted of mast cells. The remainder 0 °were composed of mixed lineages other than neutrophil/macrophage. Differential counts of representative mixed colonies compiled from several Sexperiments are presented in Table IV. The presence of several cell types within single colonies suggests that these colonies derive from pluripotent progenitor cells.
0 W h m r -52- Table IV.
Cellular composition of mixed hematopoietic colonies picked from bone marrow cultures grown in OOS-MCGF conditioned medium Differential Counts Colony Number E n m e mast M B1 36 1 22 74 64 CIO 0 0+ 004 44 0 0.0 0'400 a 040 901 4000 Differential counts of greater than 200 nucleated cells/colony. Abbreviations used are: E, erythrocyte; n, neutrophil; m, macrophage/mnocyte; e, eosinophil; mast, mast cell; M, megakaryocyte; and Bl, blast cell.
4400 x 04 06 4 0 00 Ir 0, *4 I The effects of the expressed B-9 clone were assessed on early uncommitted stem cells according to a CFU-S assay of Till and McCullock (Radiat. Res., 14: 213-222 [1961]), as modified by Schrader, and Clark-Lewis, I. of Immunol., 129: 30-35 [1982]).
When non-adherent bone marrow cells, depleted of T cells, were incubated for one week in COS-MCGF medium and injected by vein into lethally irradiated mice, macroscopic colonies appeared in the spleen (Table V).
41 1 -53- In contrast, cells incubated in supernatants of mock transfected COS-7 cells formed no colonies.
TABLE V.
Detection of CFU-S in bone marrow cells cultured for one week in COS-MCGF conditioned medium.
Spleen Supernatant added Expt. nodules/ to culture No. nmouse* CFU-S** I 4
S*
444 4 4y4r 4ar COS-7 cells transfected with full-length MCGF cDNA COS-7 cells transfected with incomplete MCGF cDNAt Mock transfected COS-7 cells 8.8 6.2 t 2.8 0.8 i 0.7 L cells Medium 0.8 E 0.7 0.7 1 0.6 0.3 k Not done 0.3 i 0.5 1 4* 4.
4 4 4 4 41*1 4 i
A.
.4,4 The mean SEM of spleen colonies detected in 5 individual 20 mice.
The mean of CFU-S calculated to reflect the frequency of CFU-S in the total culture of 3 x 106 bone marrow cells.
t Incomplete MCGF cDNA clone lacks the coding region for the
NH
2 -terminal 55 amino acids.
Light density 1.077) C57B1/6 bone marrow c.lls treated with anti-Thyl antibody and complement were plated at 1 x 106 cells/ml 0-4.
-54in Iscove's modified Dulbecco's mdium su21emented with 20% fetal calf serum, 50 W- 2-ME and 30% conditioned medium, as indicated above. Non-adherent cells were removed three times during the one-%,ek incubation period and replated in fresh medium. The cells were harvested after one week, washed twice and diluted to the original culture volume in phosphate-buffered saline. Each lethally-irradiated (1,000 R) C57B1/6 recipient was injected i.v.
with 0.1 ml of the cell suspension. After 9 days, the spleens were removed and the spleen nodules were counted using a dissecting microscope.
To summarize, in addition to the mast cell growth factor activity characterized initially, COS- MCGF has erythroid burst-promoting activity and allows Sexpansion of stem cells and early committed progenitor 15 cells of several lineages, including monocytic/granulocytic, erythroid and megakaryocytic cells. This range of activities indicates that the cDNA clones of the present invention encode proteins having the characteristics of growth factors for hematopoietic cells for multiple lineages.
From the foregoing, it will be appreciated that the cDNA clones of the present invention provide accurate and complete sequence data on mammalian multi- S. CSF and mast cell growth factors. The invention also o 25 provides to those skilled in the art means for producing significant quantities of such factors (essentially free from other hematopoietic factors) for the improved in vitro maintenance of mast cells and other hematopoietic cells. Further, the information gleaned from the cDNA clones increases understanding of the mammalian immune response, enhancing therapeutic potentialities.
Claims (23)
1. A process for producing a polypeptide exhibiting mammalian multi-lineage cellular growth factor activity and/or mammalian mast cell growth factor activity, said process comprising the steps of: a) providing a vector comprising a nucleotide sequence coding for said polypeptide, wherein the nucleotide sequence is capable of being expressed by a host containing the vector; b) incorporating the vector into the host; and c) maintaining the host containing the vector under conditions suitable for transcription of the nucleotide sequence into said polypeptide.
2. A process as claimed in claim 1 wherein the nucleotide sequence is a cDNA sequence derived from an mRNA sequence coding for said polypeptide.
3. A process as claimed in claim 1 or cla.m 2 wherein the host is a mammalian cell transformed or transfected with the vector.
4. A process as claimed in claim 3 wherein said polypeptide is glycosylated. A process as claimed in any of claims 1 to 4 wherein the vector comprises the nucleotide sequence coding for said polypeptide linked to a second nucleotide sequence, and this second nucleotide sequence comprises a promoter "A 4P 4 oil .I r I_ S-56- sequence which promotes expression of the nucleotide sequence coding for said polypeptide.
6. A process as claimed in claim 5 wherein the second nucleotide sequence comprises an SV40 virus early region promoter and an SV40 virus late region polyadenylation sequence.
7. A process as claimed in any of claims 1 to 6 wherein the nucleotide sequence codes for a polypeptide having hematopoietic cell growth activity. S 8. A process as claimed in any of claims 1 to 7 wherein the nucleotide sequence coding for said polypeptide has substantially the sequence shown in Figure 1.
9. A process as claimed in any of claims 1 to 8 wherein the nucleotide sequence coding for said polypeptide is different from but is capable of hybridizing with the 4, nucleotide sequence shown in Figure 1.
10. A process as claimed in any of claims 1 to 9 wherein the nucleotide sequence also encodes a leader sequence of the polypeptide.
11. A recombinant polypeptide consisting of at least a substantial portion of the amino acid sequence shown in Figure 1 and exhibiting mammalian multi-lineage growth factor activity and/or mammalian mast cell growth factor activity.
12. A recombinant polypeptide consisting of at least a substantial portion of the amino acid sequence shown in Figure 1 and exhibiting multi-lineage growth factor activity and/or mast cell growth factor activity on mouse cells. -2 4r 4 4 .4sai .444r 4 .444 4 l~ 4-44 4I)* 4444 4 4 -57-
13. A polypeptide as claimed in claim 11 or claim 12 in substantially pure form and essentially free from other mammalian hematopoietic cell proteins.
14. A nucleic acid sequence that codes for a polypeptide exhibiting mouse multi-lineage cellular growth factor activity and/or mast cell growth factor activity and is capable of hybridizing to a second nucleic acid sequence coding for another mammalian cellular growth factor.
15. A nucleic acid sequence as claimed in claim 14 that is a DNA sequence coding for at least a portion of the polypeptide of Figure i.
16. A nucleic acid sequence that codes for a polypeptide exhibiting mammalian multi-lineage cellular growth factor activity and/or mast cell growth factor activity and is capable of hybridizing to a second nucleic acid sequence coding for a mouse cellular growth factor.
17. A vector comprising the nucleic acid sequence of claim
18. A replicable vector capable of expressing a DNA sequence of any of claims 14 to 16, when said vector is incorporated into a microorganism or cell.
19. A microorganism or cell transformed or transfected with the replicable expression vector of claim 17 or claim 18. A pharmaceutical composition consisting of a recombinant polypeptide having mammalian multi-lineage growth factor activity and/or mammalian mast cell growth factor activity and a therapeutically compatible carrier. I -58-
21. A process for enhancing cell growth comprising contacting said cell with a recombinant polypeptide having a substantial portion of the amino acid sequence of Figure 1.
22. A process as claimed in claim 21 wherein the cell growth is enhanced in vitro.
23. A process for preparing a Folypeptide exhibiting mammalian multi-lineage cellular growth factor activity, which comprises cultivating, in an aqueous nutrient medium, a prokaryotic microorganism or eukaryotic cell I which has been transfected or transformed with a vector comprising a substantial portion of the DNA sequence shown in Figure 1. u*"t 24. A transformed microorganism or cell which contains at least a portion of a gene or other DNA sequence coding for one or more polypeptides having mammalian multi- lineage cellular growth factor activity and/or mammalian '*mast cell growth factor activity. A protein exhibiting mammalian multi-lineage cellular growth factor activity produced by cultivating the organism or cell of claim 24. S26. A recombinant DNA molecule consisting of segments of DNA from different genomes which have been joined end to end outside of living cells and have the capacity to infect some host and to be maintained therein, and the progeny thereof, comprising a DNA sequence selected from the group consisting of: a) the DNA sequence of Figure 1; b) DNA sequences which hybridize to the DNA *b\d1 >1 S- 59 sequence of Figure 1 and which code for a polypeptide exhibiting mammalian multilineage cellular growth factor activity and/or mammalian mast cell growth factor activity; and c) DNA sequences which on expression code for a protein exhibiting mammalian multilineage cellular growth fator activity and/or mammalian mast cell growth factor activity.
27. A recombinant polypeptide exhibiting human 15 multi-cellular growth factor activity and/or human mast cell growth factor activity, whose SDNA coding sequence is capable of hybridizing with DNA coding for murine IL-3. 4*49
28. A polypeptide as claimed in any of claims 11 to 13 and 27 that is capable of acting on a hematopoietic cell line. a
29. Recombinant murine IL-3 having substantially the 25 amino acid sequence shown in Figure 1 of the accompanying drawings. 9 Dated this 30th day of September 1991 SCHERING BIOTECH CORPORATION By their Patent Attorneys GRIFFITH HACK CO S:18580F/438/30.9.91 h 1 20 GGGGGGGGGG GGGAACCCCT TGGACGACCA GAACGAGACA ATG G'fl C'rr GCC MET Val Leu Ala 40 AGC TCT ACC Set Set Thr C; C ACC A'IX CTC CTC His Tht MET Leu Leu ACC AGC ATC Thr Set le so CTG CTC CTG Leu Leu Leu 100 CTC CAA CCT Leu Gin Ala 120 CCC CGC GAT ACC CAC CGT W~A Cly Arg Asp Thr His Mrg ILeu 140 ACC AGA ACG TTG Thr Arg Thr Leu ATG CTC 'rrC CAC CTG CGA MET Leu Phe His Leu Gly TCA ATC ACT Set Ile Set 160 TCT AT]T GTC Set Ile Val 180 ATA CCC AAG CTC CCA GAA CCT Ile Gly Lys Leu Pro Ciu Pro 200 GAM CTC AAA ACT CAT CAT CAA Clu Leu Lys Thr Asp Asp Giu AAT TGC AC Asn Cys Set AAG GAG ATT ELys Glu Ile 240 AAC ACC ~TT CCC AG3A GTA AMC Lys Set Phe Arg Arg Val Asn 260 CTG TCC AAA TITC CTG CAA AC Leu Set Lys Phe Val Ciu Set CTG ACC AAT7 Leu Atg Asn GGA CAA GTG CAT CCT Cly Clu Val Asp Pro 320 -TC AAT7 Crr CAC AAA CTT AAC Set Asn Leu Gin Lys Leu Asn 360 CC AATr Ala Asn 220 Gly Pro Set 300 GAG GACL AulA Ciu Asp Arg 380 CCA CCC GTC Pro Gly Val 460 ACA GTG UTa Thr Val Leu FIGURE 1 TAC CIT ATC AAG Tyr Val Ile Lys 'rGC CTG CCT ACA TCT Cys Leu Pro Thr Set CAC TCT CC cTG Asp Set Ala Leu 420 CILG ACA Leu Arg 440 CAC CTT AAC His Leu Asn 'TTC ATT CCA CAT CTC Phe Ile Arg Asp Leu CAC TTT CCC AAC vA Asp Phe Arg Lys Lys ITC 'TAC ATC GTC Phe Tyr Met Val CATr C GAG Asp Leu Glu 480 CAG CCC Gin Pro 500 Val Set Pro 520 ACC GIG, GAA TId TAA ht Val Cli: Cys. CCC TCT AGA CCA OCI Ala Ser Arg Pro Pro CCA ICT CCC TCC Ala Set Cly Set AAC CGT CCA Asn Arg Gly r "fin' 0 800 600 400 200 FIGURE 2 Fraction Number 0 0 0 0 S -C S p "-i HindHTJ SV4Oori AmpR splice junction Pst I pBR322 ori *G-C tail -Hind III1 clDNA insert poly A FIGURE 3 0 0 0.70 0 0 S MCGF coding region Hpall G-C Tail II Hind IJ BP *ii NcI A-T Tail 100 bp FIGURE 4I
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US53905083A | 1983-10-04 | 1983-10-04 | |
US539050 | 1983-10-04 | ||
US590867 | 1984-03-19 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU33756/84A Division AU3375684A (en) | 1983-10-04 | 1984-10-02 | Cdna clones for growth factor polypeptide |
Publications (2)
Publication Number | Publication Date |
---|---|
AU4443989A AU4443989A (en) | 1990-03-08 |
AU618143B2 true AU618143B2 (en) | 1991-12-12 |
Family
ID=24149548
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU44439/89A Ceased AU618143B2 (en) | 1983-10-04 | 1989-11-06 | Cdna clones coding for polypeptides exhibiting multi- lineage cellular growth factor activity and/or mast cell growth factor activity |
Country Status (3)
Country | Link |
---|---|
JP (1) | JPS60176597A (en) |
AU (1) | AU618143B2 (en) |
ZA (1) | ZA847718B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63245667A (en) * | 1987-03-31 | 1988-10-12 | Ube Ind Ltd | Human cell capable of producing human il-3 having mast cell proliferation activity and production of human il-3 having mast cell proliferation activity |
-
1984
- 1984-10-01 ZA ZA847718A patent/ZA847718B/en unknown
- 1984-10-02 JP JP59206976A patent/JPS60176597A/en active Pending
-
1989
- 1989-11-06 AU AU44439/89A patent/AU618143B2/en not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
JPS60176597A (en) | 1985-09-10 |
ZA847718B (en) | 1985-05-29 |
AU4443989A (en) | 1990-03-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0138133B1 (en) | Cdna clones coding for polypeptides exhibiting multi-lineage cellular growth factor activity and/or mast cell growth factor activity | |
Brakenhoff et al. | Molecular cloning and expression of hybridoma growth factor in Escherichia coli. | |
JP2568394B2 (en) | A nucleic acid comprising a nucleotide sequence encoding a polypeptide exhibiting mammalian interleukin-4 activity | |
Campbell et al. | Isolation, structure and expression of cDNA and genomic clones for murine eosinophil differentiation factor: Comparison with other eosinophilopoietic lymphokines and identity with interleukin‐5 | |
FI103986B (en) | cDNA clones encoding polypeptides having human cellular granulocyte macrophage and eosinophilic growth factor activity | |
NZ225411A (en) | Hgm-csf human granulocyte macrophage colony stimulating factor and vector for its expression containing the sr#a# promoter of the plasmid deposited in atcc67318 | |
US5951973A (en) | Use of interleukin-4 (IL-4) to treat rheumatoid arthritis | |
AU618143B2 (en) | Cdna clones coding for polypeptides exhibiting multi- lineage cellular growth factor activity and/or mast cell growth factor activity | |
US5955315A (en) | Nucleic acids encoding human interleukin-4 | |
Kajigaya et al. | A recombinant murine granulocyte/macrophage (GM) colony-stimulating factor derived from an inducer T cell line (IH5. 5). Functional restriction to GM progenitor cells. | |
US4798789A (en) | cDNA clones coding for polypeptides exhibiting murine interleukin-2 activity | |
AU599891B2 (en) | CDNA clones coding for polypeptides exhibiting murine interleukin-2 activity | |
AU626530B2 (en) | Human granulocyte-macrophage colony stimulating factor and muteins thereof | |
EP0267779A2 (en) | Human pleiotropic immune factor and muteins thereof | |
Abraham | Activation of multiple hemopoietic growth factor genes in Abelson virus transformed myeloid cells | |
CA1341299C (en) | Mammalian interleukin-4 |